Are stable producer cells the future of viral vector manufacturing and when will allogeneic cell therapy take hold? – BioPharma-Reporter.com

The publication, based on data generated from a questionnaire with 150 industry representatives, explores the challenges and solutions facing cell and gene therapy (CGT) companies over the next few years.

The top six trends identified in the CRB survey were:

We got the inside track from Noel Maestre, director of SlateXpace, a CRB solution focused on suite-based manufacturing platforms for the Advanced Therapy Medicinal Products (ATMP) and Peter Walters, CRBs director of ATMP, on how the CGT landscape is likely to develop in the short-term.

In a recent report, the MITs Center for Biomedical Innovationprojected that around 500,000 patients will have been treated with 40-60 approved gene therapies by 2030.

Going from the current scenario whereby only a few gene therapies are approved to 60 launches in a decade would represent an extraordinary leap forward and would dramatically change how medicine is actually perceived, said Maestre.

But as regards CGT production today, especially autologous cell therapy (ACT) work, he said that while the science exists the technology - process equipment, facility design and automation platforms - is really still trying to catch up, endeavoring to address a sector that has exploded in the past five years, he commented.

Looking ahead at the CGT landscape over the next few years, he expects a significant amount of change. The science is evolving we see the industry moving away from old cell lines to new cell lines or moving away from viral vectors altogether and using cleavage enzymes as a gene editing tool.

A new host cell line stable producer lines is gaining momentum, he said.

We are seeing the industry moving towards suspension cell culture from less than optimal cell lines, and then further going into producer cell lines.

A full 65% of respondents to the CRB poll said they are developing or intend to develop this type of vector host cell, drawn by the potential for a less expensive, more scalable process.

CRB: Our survey findings provide a data-driven snapshot of an industry whose intellectual capital and cutting-edge science is too often betrayed by outdated technology and applications ill-suited for commercial scale at a time when demand for urgent therapies is rising.

Once the industry gets to the point where producer cell lines are more like a name brand, easier to pull off the shelf and use, it will be a much more cost-effective way to produce viral vectors.

But we are right on the cusp - a lot of companies are recognizing the opportunity and are investing the time and money into producing these. And we also see a lot of contract development and manufacturing organizations (CDMOs) producing their own cell lines in house and using those as a lure to [attract the clinical material work] of their clients, said Walters.

According to Maestre, and the CRB survey data backs him up, the product pipelines of companies operating in the CGT space are going to get more complex, for the next five years at least.

More than half of those polled indicated they expect to adopt a multimodal solution within the next two years, with flexibility, scalability, operational efficiency, and speed to market as the top drivers.

Every company is going to be dealing with this dilemma of whether they build dedicated spaces for each of their different modalities, or whether they build highly flexible facilities that can allow them to accommodate whatever is coming next, said Maestre.

He also sees a lot more companies wanting to integrate their supply chain, bringing a lot of manufacturing in-house whereas before they would have been reliant on a whole set of different CDMOs and manufacturers.

Project delivery is also where change is occurring.

We are seeing the industry really moving away from the way projects were executed in the past into a much more integrated model; they are looking for turnkey facility delivery and they want turnaround to be faster. COVID-19 has only accentuated that, with project timelines compressed by 30-40%, and I dont think that it is ever going back to the way it was I think that is going to become the standard, commented Maestre.

And another major trend over the next few years will be around the cost of therapies. As they become more commonplace and there are more and more CGT licensed products, the costs will come down.

Projecting forward, Walters sees an eventual shift away from autologous to allogeneic cell therapy.

As the technology continues to develop and the science continues to improve and new and better ways are found to use and leverage cells, we will see companies moving to a scalable allogeneic model, getting away from having to do that point-of-care, personalized tracking and more towards a classic manufacturing model that allows them to produce cells in advance in a way that they can be scaled up.

The idea, evidently, is to process cells for not one but dozens of patients at a time.

We see the industry moving towards donated cells for allogeneic therapy and we are also seeing the beginnings of a shift to using stem cells that can be genetically modified and scaled up and differentiated to become T-Cells or NK cells. I dont think industry has settled on a course yet but there are a lot of companies trying to find that pathway, trying to find the edge to move their manufacturing platform that way, remarked Walters.

Right now, though, all facets of CGT manufacturing are under pressure from COVID-19 vaccine production, they said.

There is significant shortage of cleanroom manufacturing space to manufacture and develop the almost 1,200 CGT products in clinical trials currently.

What we are seeing is that CDMOs have so much demand - they have 12-18 months of backlog in terms of contracts for product development so they are building [new facilities] very rapidly.

As owner operator companies are stuck with that delay in getting their products into development, they are also developing a significant amount of manufacturing space on their own. But while both branches are building as fast as they can, it still isnt enough.

We are constantly hearing from our clients that they are concerned about their supply chains and being able to secure their material. Right now, a lot of companies are moving towards a combination of using CDMOs and manufacturing in-house, said Maestre.

CRB is a provider of engineering, architecture, construction and consulting solutions to the global life sciences and advanced technology industries, with over 1,300 employees.

Visit link:

Are stable producer cells the future of viral vector manufacturing and when will allogeneic cell therapy take hold? - BioPharma-Reporter.com

Global Stem Cell Therapy Market Detailed Analysis Of Current Industry Figures With Forecasts Growth By 2027 – The Haitian-Caribbean News Network

Coherent Market Insights Presents GlobalStem Cell Therapy MarketSize, Status and Forecast 2020-2027 New Document to its Studies Database

This report, which has been published, is having a meaningful Stem Cell Therapy market insight. It casts some lights on industry products and services. Along with those product applications, it also examined whether it reaches up to the end-users or not. This report on this Stem Cell Therapy market has given an overall view of the recent technologies used and technological improvements. It also focuses on recent industry trends and which products are quite demanding from a customers perspective. This report is focused on every aspect of the forecast year 2027.

This report is representing a whole market scenario on a global basis. In this report, we can also find the analysis growth of industries. Through this report, we can easily interpreter the level of market competition, different pricing models, the latest market trends, customer demand, etc. This report acknowledges the revenue model and market expansion of this Stem Cell Therapy market. If you want to get that full market information, then this report can help you. It also gives a comprehensive knowledge about the demand and supply graph. Suppose that demand curves moved downward, then from this report, you can know about those factors responsible for its decline.

Get 15% Free Customization on this Report: https://www.coherentmarketinsights.com/insight/request-customization/2848

Competitive Landscape and Stem Cell Therapy Market Share Analysis

Stem Cell Therapy market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2016-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2016-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Stem Cell Therapy business, the date to enter into the Stem Cell Therapy market, Stem Cell Therapy product introduction, recent developments, etc.

Some of the key players/Manufacturers involved in the Stem Cell Therapy MarketMagellan, Medipost Co., Ltd, Osiris Therapeutics, Inc., Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Anterogen Co. Ltd., Pharmicell Co., Inc., and Stemedica Cell Technologies, Inc.

Research and Methodology

For the research, the Stem Cell Therapy markets research teams are adopted various high-end techniques. Industry best analysts are worked on this report. They collected data from various reliable sources and have taken samples of different market segments. They utilize both qualitative and quantitative data in this report. All data are based on primary sources, which are focused on the assessment year 2020-2027. For wise decision-making, they have also done SWOT analysis, which can also help them know their predicted future results. This report also helps to develop Stem Cell Therapy market growth by improvising its strategic models.

Detailed Segmentation:

By Cell Source:

By Application:

If opting for the Global version of Stem Cell Therapy Market analysis is provided for major regions as follows:

North America (The US, Canada, and Mexico)

Europe (the UK, Germany, France, and Rest of Europe)

Asia Pacific (China, India, and Rest of Asia Pacific)

Latin America (Brazil and Rest of Latin America)

Middle East & Africa (Saudi Arabia, the UAE, South Africa, and Rest of Middle East & Africa)

Key Benefits:

This study gives a detailed analysis of drivers and factors limiting the market expansion of Stem Cell Therapy

The micro-level analysis is conducted based on its product types, end-user applications, and geographies

Porters five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players

By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Stem Cell Therapy market

Buy This Complete A Business Report:https://www.coherentmarketinsights.com/insight/buy-now/2848

Reasons to Buy a Full Report In depth analysis by industry experts Use of data triangulation method for examining the various aspects of the market Detailed profiling of the major competitors in the market A complete overview of the market landscape Computed Annual Growth Rate is calculated for period, 2020-2027

Table of Contents

Report Overview: It includes the Stem Cell Therapy market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary: This section of the report gives information about Stem Cell Therapy market trends and shares, market size analysis by region and analysis of global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players: Here, key players of the Stem Cell Therapy market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study: All of the regions and countries analyzed in the Stem Cell Therapy market report is studied on the basis of market size by application, the market size by product, key players, and market forecast.

Actual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.

Contacts US:

Mr. ShahCoherent Market Insights,1001 4th Ave,#3200 Seattle, WA 98154, U.S.Phone: US +1-206-701-6702/UK +44-020 8133 4027Email:[emailprotected]

Link:

Global Stem Cell Therapy Market Detailed Analysis Of Current Industry Figures With Forecasts Growth By 2027 - The Haitian-Caribbean News Network

Not All Patients With Relapsed DLBCL Referred for CAR T in Community Setting – Targeted Oncology

Hematologists and oncologists working in the community setting encounter multiple obstacles when prescribing chimeric antigen receptor (CAR) T-cell therapy to patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The challenges involve matters of processes, treatment cost, and access to treatment.

To further understand the issues and the solutions needed for physicians who treat relapsed/refractory DLBCL, researchers at Cardinal Health conducted 2 live survey sessions to collect information from clinicians. A total of 114 oncologists and hematologists from community practices and hospital settings participated in the survey. The population of hematologists/oncologists see roughly 20 patients per day, and the majority have been in practice for 11 to 20 years. Overall, 46% of the clinicians who attended the first live survey session, and 26% of those who attended the second reported that they had not referrer any patient for CAR T-cell therapy, and of those who did refer patients 32% and 22% of patients, respectively had not yet been infused with CAR T cells.1

The results of the survey revealed that while the use of CAR T-cell therapy increased in community practices over the past year, there remain issues with high cost and toxicity of treatment. It was also reported that the processing of insurance was a barrier to getting patients treated. These challenges continue to limit the number of clinicians who recommend CAR T-cell therapy to their patients.

In an interview withTargeted Oncology, Ajeet Gajra, MD, FACP, vice president, Cardinal Health, discussed the ongoing challenges community oncologists face with prescribing CAR T-cell therapy to patients with relapsed/refractory DLBCL.

TARGETED ONCOLOGY: Can you explain the overall prognosis for patients with DLBCL? What are outcomes generally like with existing standard of care therapy?

Gajra: The outlook for DLBCL improved with the advent of chemoimmunotherapy, better risk stratification, and improved supportive care. Recent studies demonstrate that despite aggressive biology, over 60% of patients with DLBCL treated with chemoimmunotherapy achieve long-term remissions and cures. However, the improvements reached a plateau in the past decade, especially for patients who relapse after initial chemoimmunotherapy. These patients typically have poor prognostic features as defined by the International Prognostic Index (IPI) with high likelihood of relapse and death. Patients with relapsed or refractory disease are typically treated with salvage immunochemotherapy such as rituximab, ifosfamide, carboplatin and etoposide (RICE) or rituximab, cisplatin high dose Ara-C and dexamethasone (RDHAP), and those with chemotherapy-sensitive disease receive autologous stem cell transplant (ASCT). Using this approach, complete response (CR) rates are 35% to 40%, and in a recent study the 3-year event-free survival (EFS) and overall survival (OS) were 31% and 50%, respectively. Outcomes with ASCT are much worse for patients with refractory DLBCL as demonstrated in the SCHOLAR trial wherein the objective response rate was 26% (CR rate, 7%) with a median OS of 6.3 months and only 20% of patients were alive at 2 years.

Thus, prior to 2017 when the first CAR T therapy was approved in DLBCL with progression after 2 prior lines of therapy, there had been a significant unmet need for patients with relapsed DLBCL. The approval of 2 CAR-T therapies, axicabtagene ciloleucel (axi-cel) in October of 2017 and tisagenlecleucel (Kymriah; tisa-cel) in May 2018, in the treatment of large-cell lymphoma (LBCL), has ushered in a new mode of treatment which offers the potential of long-term remission in what was essentially a fatal disease.

TARGETED ONCOLOGY: What has been your observation experience with using CAR T cell therapy in patients with DLBCL by US community oncologists?

Gajra: Axi-cel and tisa-cel are both CD19-directed, genetically modified autologous T cell immunotherapy agents. Since the process of obtaining CAR T therapy for an individual patient is quite complex, we sought to assess the uptake of these agents among United States community oncologists. We conducted a study of community oncologists at two time points to assess perceptions and use of approved CAR T therapies in relapsed DLBCL. At each time point over 50 distinct oncologists participated. At the early timepoint, 46% of participants indicated that they had not referred any patients for CAR T therapy but at the later timepoint, this number decreased to 29% suggesting increasing use over the course of the 10-month interval. Of those participants who had referred patients for CAR T therapy, 32% at the early timepoint reported that none of their patients had yet received the CAR T infusion but the percentage of non-receipt decreased to 22% at the later timepoint again suggesting improved uptake and utilization.

TARGETED ONCLOGY: How do patient characteristics factor into how oncologists select patients to administer CAR T cells to? What are the barriers to CAR-T use?

Gajra: CAR T therapies approved in DLBCL have limitations as defined by the FDA approval and are to be used in adult patients with relapsed or refractory large B-cell lymphoma, including DLBCL, after 2 or more lines of systemic therapy. Neither agent is approved for the use of CNS lymphoma. As with the pivotal trials for the 2 agents, patients must have good ECOG performance status, adequate organ function including marrow, hepatic, cardiac and renal function, no active infection and no CNS involvement. Both agents carry black box warnings for neurotoxicity and cytokine release syndrome (CRS) which can be potentially fatal. Thus, the patients selected need to have good physiologic reserve and be willing to accept risks associated with the therapies. With the approval of a new CD19-directed monoclonal antibody, tafasitamab, it is not clear if patients exposed to that agent can still benefit from CAR T therapies.

In addition to patient specific factors, CAR T therapy represents a complex manufacturing process that is unlike traditional drug therapy or stem cell transplant. After identification of a potential patient with relapsed LBCL who has received at least two prior systemic therapies, a benefits verification and referral to a designated CAR T-cell therapy center is required. If deemed appropriate by the CAR T center, the patient undergoes apheresis for T-cell collection. The cells are then transported to the manufacturers facility where they are isolated, activated and undergo gene transfer, creating the chimeric cells which go through a process of expansion to generate the numbers needed for therapeutic effect. This process takes from 10 days to a few weeks. The CAR T cells are then cryopreserved and transferred back to the CAR T facility and reinfused into the patient. Thus, it is critical to maintain vein to vein integrity. Thus, unlike traditional cytotoxic or monoclonal antibody products, these agents are patient specific, living cell products that have a complex process for their manufacture, storage and shipping, leading to high costs to the healthcare system and the patient.

Given this information, not surprisingly, the oncologists surveyed identified the high cost of therapy as a major barrier to uptake and utilization at both time points respectively. Over half the participants identified cumbersome logistics of administering therapy and following patients as another major barrier. Further exploration of logistical issues identified barriers encountered during the referral process could be attributed to the payer or the CAR T center.

The payer specific challenges identified include slow approval process by 27% of payers (and high rates of denials by in 13% of payers. The challenges specific to the CAR-T center include slow intake process by 23% of CAR T centers lack of a CAR T center in geographic vicinity in 13%. CAR T center choosing stem cell transplant rather than CAR T for the patient was also seen 10% of the time. Other commonly encountered clinical challenges reported by the participants included deterioration of the patient prior to CAR T administration, and the need to administer bridging chemotherapy while awaiting manufacture of CAR T therapy. The lack of communication from the CAR T center during the process was identified by a minority as an impediment to recommending CAR T therapies, including lack of instructions to the primary oncologist and the patient.

TARGETED ONCOLOGY: Can you discuss the toxicities observed with CAR T cell therapy in this patient population? Do you haveany insight into toxicities observed in the real-world setting?

Gajra: As stated, both approved products carry black box warnings for CRS and neurotoxicity, now called Immune Effector Cell Associated Neurologic Syndrome (ICANS). CRS is an acute systemic inflammatory syndrome characterized by fever, hypotension, tachycardia, hypoxia and multiple organ dysfunction. ICANS is a neuropsychiatric complex manifested by encephalopathy, headache, tremor, dizziness, aphasia, delirium, insomnia and anxiety. The treating team needs to maintain a high index of suspicion for these potentially life-threatening agents and patients need to have access to facilities with advanced critical care. Tumor debulking ahead of CAR T infusion and prophylactic use of tocilizumab may reduce the risk of CRS. Use of corticosteroids early can alleviate the severity and duration of ICANS.

The scientific team at Cardinal Health has studied the real-world adverse events (AEs) to CAR T agents in DLBCL.2 We analyzed the postmarketing case reports from the FDA, AEs reporting system involving axicel and tisa-cel for large B-cell lymphomas were analyzed. Of 804 AE cases identified 67% of axi-cel cases and 26% of tisa-cel cases reported neurological AEs. Compared with cases without neurological AEs, significant associations were observed between neurological AEs and use of axi-cel, age 65 years, CRS and the outcome of hospitalization. These findings and those of other investigators suggest that there may be differences in neurological toxicity based on the agent used.

TARGETED ONCOLOGY: Can you provide background on how this web-based survey can about at Cardinal Health Specialty Solutions? What is the overall goal with it?

Gajra: We are continuously engaged in research with healthcare providers, including medical oncologists/hematologists, to assess their perspectives on issues they face in their day-to-day practice, including the impact of new therapies on patient care. We share our research findings with healthcare stakeholders through peer-reviewed manuscripts and abstracts, as well as through our Oncology Insights report, which is published twice a year.

TARGETED ONCOLOGY:How can the information obtained from this survey impact practice? Where are you in the process of response collect and obtaining results?

Gajra: Our research on CAR-T therapy, collected via web-based and in-person surveys, has helped us identify the challenges to the use of these therapies encountered by community oncologists. Given that over 50% of cancer care is rendered in the community setting, it is important to identify these barriers with a goal of mitigating them and facilitating timely access to these potentially life-saving therapies for patients. With a new CAR-T approval in mantle cell lymphoma this year and other potential approvals in newer indications on the horizon, streamlining access to CAR-T therapies will continue to be a priority.

We have a follow-up to this paper that will be presented at ASH 2020 where additional research with community oncologists in early 2020 has revealed that the rate of non-receipt of CAR-T therapies in DLBCL is relatively constant at around 30%. In addition, we are exploring interest and uptake of CAR-T therapies in the outpatient setting as oncologists gain more confidence in preventing, minimizing and managing the toxicity of CAR-T therapies.

References:

1. Gajra A, Jeune-Smith Y, Yeh T, et al. Perceptions of community hematologists/oncologists on barriers to chimeric antigen receptor T-celltherapy for the treatment of diffuse large B-cell lymphoma. Immunotherapy. 202012(10);725-732. doi: 10.2217/imt-2020-0118

2. Gajra A, Zettler ME, Phillips EG Jr, Klink AJ, Jonathan K Kish, Fortier S, Mehta S, Feinberg BA. Neurological adverse events following CAR T-cell therapy: a real-world analysis. Immunotherapy. 2020 Oct;12(14):1077-1082. doi: 10.2217/imt-2020-0161

Read the rest here:

Not All Patients With Relapsed DLBCL Referred for CAR T in Community Setting - Targeted Oncology

CRISPR and another genetic strategy fix cell defects in two common blood disorders – Science Magazine

Victoria Gray (right), shown with researcher Haydar Frangoul, was the first patient to be treated with the gene-editing tool CRISPR for sickle cell disease.

By Jocelyn KaiserDec. 5, 2020 , 12:30 PM

It is a double milestone: new evidence that cures are possible for many people born with sickle cell disease and another serious blood disorder, beta-thalassemia, and a first for the genome editor CRISPR.

In todays issue of The New England Journal of Medicine (NEJM) and tomorrow at the American Society of Hematology (ASH) meeting, teams report that two strategies for directly fixing malfunctioning blood cells have dramatically improved the health of a handful of people with these genetic diseases. One relies on CRISPR, marking the first inherited disease treated with the powerful tool created just 8 years ago. And both treatments are among a wave of genetic strategies poised to widely expand who can be freed of the two conditions. The only current cure, a bone marrow transplant, is risky, and appropriately matched donors are often scarce.

The novel genetic treatments still need longer folllow up, have the same safety issues as bone marrow transplants for now, and may also be extraordinarily expensive, but there is hope those risks can be eliminated and the costs pared down. This is an amazing time, and its exciting because its happening all at once, says hematologist Alexis Thompson of Northwestern University, who with a company called Bluebird Bio continues to test yet another genetic strategy that first demonstrated a sickle cell fix several years ago.

People born with sickle cell disease have mutations in their two copies of a gene for hemoglobin, the oxygen-carrying protein in red blood cells. The altered proteins stiffen normally flexible red blood cells into a sicklelike shape. The cells can clog blood vessels, triggering severe pain and raising the risk of organ damage and strokes. Sickle cell disease is among the most common inherited diseases, affecting 100,000 Black people in the United States alone. (The sickling mutations became widespread in African people, as one copy protects blood cells from malaria parasites.)

People with beta-thalassemia make little or no functioning hemoglobin, because of other mutations that affect the same subunit of the protein. About 60,000 babies are born each year globally with symptoms of the disease, largely of Mediterranean, Middle Eastern, and South Asian ancestry. Blood transfusions are standard treatment for both diseases, relieving the severe anemia they can cause, and drugs can somewhat reduce the debilitating crises that often send sickle cell patients to the hospital.

In the two new treatments, investigators have tinkered with genes to counter the malfunctioning hemoglobin. They remove a patients blood stem cells and, in the lab, disable a genetic switch called BCL11A that, early in life, shuts off the gene for a fetal form of hemoglobin. The patient then receives chemotherapy to wipe out their diseased cells, and the altered stem cells are infused. With the fetal gene now active, the fetal proteinrestores missing hemoglobin in thalassemia.In sickle cell disease it replaces some of the flawed adult sickling hemoglobin, and also blocks any remaining from forming sticky polymers.

Its enough to dilute the effect, says Samarth Kulkarni, CEO of CRISPR Therapeutics, which partnered with Vertex Pharmaceuticals on using the genome editor.

They engineered CRISPRs DNA-cutting enzyme and guide RNA to home in on and break the BCL11A gene. In a more traditional gene therapy effort, a team led by gene therapy researcher David Williams of Boston Childrens Hospital achieved the same goal. They used a harmless virus to paste into the blood stem cells genome a stretch of DNA coding for a strand of RNA that silences the fetal hemoglobin off switch.

Patients treated in both trials have begun to make sufficiently high levels of fetal hemoglobin and no longer have sickle cell crises or, in all but a single case, a need for transfusions. In one NEJM paper today, the Boston Childrens team reports on the success of its virus gene therapy in six sickle cell patients treated for at least 6 months. They include a teenager who can now go swimming without pain, and a young man who once needed transfusions but has gone without them nearly 2.5 years, says Erica Esrick of Boston Childrens. He feels perfectly normal.

CRISPR appears to have done at least as well. The first sickle cell patient to receive CRISPR 17 months ago, a Mississippi mother of four named Victoria Gray, has called the results wonderful. We have amelioratedthe symptoms, says Haydar Frangoul, a hematologist at the Sarah Cannon Research Institute who treated Gray as part of the CRISPR trial. Every time I call her on the phone or see her in the clinic, she feels great.

CRISPR Therapeutics and Vertex describe the results for Gray and one beta-thalassemia patient treated 22 months ago today in another NEJM paper, and Frangoul will report on seven beta-thalassemia and three sickle cell patients tomorrow at the online ASH meeting. The CRISPR results are really very impressive, says Boston Children's stem cell biologist Stuart Orkin, whose lab discovered the BCL11A switch that led to both trials. (He is not directly involved with either.)

The results are comparable to the older strategy from Bluebird that relies on a different genetic alteration: adding a gene for an adult hemoglobin that has been tweaked so it reduces polymerization of the sickling form. At the ASH meeting, Thompson will give an update on about two dozen sickle cell disease patients who received the treatment within the past 3 years. As of March, the 14 with a follow-up of 6 months or more had experienced just a single mild pain crisis overall.

The Bluebird treatment was approved in Europe in 2019 for certain beta-thalassemia patients, and the company expects to seek Food and Drug Administration approval in the United States for its products for both diseases within the next few years. Bluebird chief scientific officer Philip Gregory says the long-term data for the firm's treatment give it an advantage over the newer approaches. Weve set a very high bar, he says.

Others who treat these diseases say its too early to crown a specific genetic treatment the winner. For example, reversing the fetal hemoglobin off switch, as the new CRISPR and RNA-based gene therapy strategies do, allows blood cells to make natural levels of the protein. But so far there are no signs that Bluebirds treatment results in excess adult hemoglobin that causes problems, Williams says. And although a virus-carrying gene can land in the wrong place and trigger cancer, CRISPR could similarly make harmful off-target edits. There has been no sign of that. Still, We need long-term follow-up for all the strategies, says the National Institutes of Healths (NIHs) John Tisdale, a coleader of the Bluebird study.

None of these genetic treatments seems likely to immediately help the many patients in places like Africa and India who dont have access to sophisticated health care. Itswonderful, but it wont solve the global health problem, Orkin says. Bluebird expects to charge $1.8 million for LentiGlobin in Europea sum it derived from looking at a patients gains in life span and quality of lifeand the other genetic treatments are likely to be similarly expensive. Costs will also include the chemotherapy needed to eliminate patients diseased blood stem cells, and the attendant hospital stay.

Bluebird and other groups are exploring whether antibodies, instead of harsh chemotherapy, can wipe out a patients diseased cells. In a bolder effort, NIH and the Bill & Melinda Gates Foundation last year announced a plan to put at least $100 million into developing technologies that would modify blood stem cells in a patients bone marrow by injecting the gene-editing tools themselves into the body. Its a big hairy goal, but its an engineering challenge, says gene therapy researcher Donald Kohn of the University of California, Los Angeles, who leads another sickle cell treatment trial. Well get there.

Here is the original post:

CRISPR and another genetic strategy fix cell defects in two common blood disorders - Science Magazine

Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19) – Cheshire Media

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Cell Therapy market.

Trusted Business Insights presents an updated and Latest Study on Cell Therapy Market 2020-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Cell Therapy market during the forecast period (2020-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Cell Therapy Market

The global cell therapy market size was valued at USD 5.8 billion in 2019 and is projected to witness a CAGR of 5.4% during the forecast period. The development of precision medicine and advancements in Advanced Therapies Medicinal Products (ATMPS) in context to their efficiency and manufacturing are expected to be the major drivers for the market. In addition, automation in adult stem cell and cord blood processing and storage are the key technological advancements that have supported the growth of the market for cell therapy.

The investment in technological advancements for decentralizing manufacturing of this therapy is anticipated to significantly benefit the market. Miltenyi Biotec is one of the companies that has contributed to the decentralization in manufacturing through its CliniMACS Prodigy device. The device is an all-in-one automated manufacturing system that exhibits the capability of manufacturing various cell types.

An increase in financing and investments in the space to support the launch of new companies is expected to boost the organic revenue growth in the market for cell therapy. For instance, in July 2019, Bayer invested USD 215 million for the launch of Century Therapeutics, a U.S.-based biotechnology startup that aimed at developing therapies for solid tumors and blood cancer. Funding was further increased to USD 250 billion by a USD 35 million contribution from Versant Ventures and Fujifilm Cellular Dynamics.

The biomanufacturing companies are working in collaboration with customers and other stakeholders to enhance the clinical development and commercial manufacturing of these therapies. Biomanufacturers and OEMs such as GE healthcare are providing end-to-end flexible technology solutions to accelerate the rapid launch of therapies in the market for cell therapy.

The expanding stem cells arena has also triggered the entry of new players in the market for cell therapy. Celularity, Century Therapeutics, Rubius Therapeutics, ViaCyte, Fate Therapeutics, ReNeuron, Magenta Therapeutics, Frequency Therapeutics, Promethera Biosciences, and Cellular Dynamics are some startups that have begun their business in this arena lately.

Use-type Insights

The clinical-use segment is expected to grow lucratively during the forecast period owing to the expanding pipeline for therapies. The number of cancer cellular therapies in the pipeline rose from 753 in 2018 to 1,011 in 2019, as per Cancer Research Institute (CRI). The major application of stem cell treatment is hematopoietic stem cell transplantation for the treatment of the immune system and blood disorders for cancer patients.

In Europe, blood stem cells are used for the treatment of more than 26,000 patients each year. These factors have driven the revenue for malignancies and autoimmune disorders segment. Currently, most of the stem cells used are derived from bone marrow, blood, and umbilical cord resulting in the larger revenue share in this segment.

On the other hand, cell lines, such as Induced Pluripotent Stem Cells (iPSC) and human Embryonic Stem Cells (hESC) are recognized to possess high growth potential. As a result, a several research entities and companies are making significant investments in R&D pertaining to iPSC- and hESC-derived products.

Therapy Type Insights of Cell Therapy Market

An inclination of physicians towards therapeutic use of autologous and allogeneic cord blood coupled with rising awareness about the use of cord cells and tissues across various therapeutic areas is driving revenue generation. Currently, the allogeneic therapies segment accounted for the largest share in 2019 in the cell therapy market. The presence of a substantial number of approved products for clinical use has led to the large revenue share of this segment.

Furthermore, the practice of autologous tissue transplantation is restricted by the limited availability of healthy tissue in the patient. Moreover, this type of tissue transplantation is not recommended for young patients wherein tissues are in the growth and development phase. Allogeneic tissue transplantation has effectively addressed the above-mentioned challenges associated with the use of autologous transplantation.

However, autologous therapies are growing at the fastest growth rate owing to various advantages over allogeneic therapies, which are expected to boost adoption in this segment. Various advantages include easy availability, no need for HLA-matched donor identification, lower risk of life-threatening complications, a rare occurrence of graft failure, and low mortality rate.

Regional Insights of Cell Therapy Market

The presence of leading universities such as the Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, and Yale Stem Cell Center that support research activities in U.S. is one of the key factor driving the market for cell therapy in North America. Moreover, strong regulatory and financing support from the federal bodies for expansion of this arena in U.S. as well as Canada is driving the market.In Asia Pacific, the market is anticipated to emerge as a lucrative source of revenue owing to the availability of therapies at lower prices coupled with growing awareness among the healthcare entities and patients pertaining the potential of these therapies in chronic disease management. Japan is leading the Asian market for cell therapy, which can be attributed to its fast growth as a hub for research on regenerative medicine.

Moreover, the Japan government has recognized regenerative medicine and cell therapy as a key contributor to the countrys economic growth. This has positively influenced the attention of global players towards the Asian market, thereby driving marketing operations in the region.

Market Share Insights of Cell Therapy Market

Some key companies operating in this market for cell therapy are Fibrocell Science, Inc.; JCR Pharmaceuticals Co. Ltd.; Kolon TissueGene, Inc.; PHARMICELL Co., Ltd.; Osiris Therapeutics, Inc.; MEDIPOST; Cells for Cells; NuVasive, Inc.; Stemedica Cell Technologies, Inc.; Vericel Corporation; and ANTEROGEN.CO.,LTD. These companies are collaborating with the blood centers and plasma collection centers in order to obtain cells for use in therapeutics development.

Several companies have marked their presence in the market by acquiring small and emerging therapy developers. For instance, in August 2019, Bayer acquired BlueRock Therapeutics to establish its position in the market for cell therapy. BlueRock Therapeutics is a U.S. company that relies on a proprietary induced pluripotent stem cell (iPSC) platform for cell therapy development.

Several companies are making an entry in the space through the Contract Development and Manufacturing Organization (CDMO) business model. For example, in April 2019, Hitachi Chemical Co. Ltd. acquired apceth Biopharma GmbH to expand its global footprint in the CDMO market for cell and gene therapy manufacturing.

In September 2020, Takeda Pharmaceutical Company Limited announced the expansion of its cell therapy manufacturing capabilities with the opening of a new 24,000 square-foot R&D cell therapy manufacturing facility at its R&D headquarters in Boston, Massachusetts. The facility provides end-to-end research and development capabilities and will accelerate Takedas efforts to develop next-generation cell therapies, initially focused on oncology with the potential to expand into other therapeutic areas.

The R&D cell therapy manufacturing facility will produce cell therapies for clinical evaluation from discovery through pivotal Phase 2b trials. The current Good Manufacturing Practices (cGMP) facility is designed to meet all U.S., E.U., and Japanese regulatory requirements for cell therapy manufacturing to support Takeda clinical trials around the world.

The proximity and structure of Takedas cell therapy teams allow them to quickly apply what they learn across a diverse portfolio of next-generation cell therapies including CAR NKs, armored CAR-Ts, and gamma delta T cells. Insights gained in manufacturing and clinical development can be quickly shared across global research, manufacturing, and quality teams, a critical ability in their effort to deliver potentially transformative treatments to patients as fast as possible.

Takeda and MD Anderson are developing a potential best-in-class allogeneic cell therapy product (TAK-007), a Phase 1/2 CD19-targeted chimeric antigen receptor-directed natural killer (CAR-NK) cell therapy with the potential for off-the-shelf use being studied in patients with relapsed or refractory non-Hodgkins lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Two additional Phase 1 studies of Takeda cell therapy programs were also recently initiated: 19(T2)28z1xx CAR T cells (TAK-940), a next-generation CAR-T signaling domain developed in partnership with Memorial Sloan Kettering Cancer Center (MSK) to treat relapsed/refractory B-cell cancers, and a cytokine and chemokine armored CAR-T (TAK-102) developed in partnership with Noile-Immune Biotech to treat GPC3-expressing previously treated solid tumors.

Takedas Cell Therapy Translational Engine (CTTE) connects clinical translational science, product design, development, and manufacturing through each phase of research, development, and commercialization. It provides bioengineering, chemistry, manufacturing and control (CMC), data management, analytical and clinical and translational capabilities in a single footprint to overcome many of the manufacturing challenges experienced in cell therapy development.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Cell Therapy Market Research ReportThis report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2019 to 2030. For the purpose of this study, this market research report has segmented the global cell therapy market on the basis of use-type, therapy-type, and region:

Use-Type Outlook (Revenue, USD Million, 2019 2030)

Clinical-use

By Therapeutic Area

By Cell Type

Non-stem Cell Therapies

Therapy Type Outlook (Revenue, USD Million, 2019 2030)

Looking for more? Check out our repository for all available reports on Cell Therapy in related sectors.

Quick Read Table of Contents of this Report @ Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Read more from the original source:

Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19) - Cheshire Media

UCLA receives $7.3 million grant to build state-of-the-art facility for developing gene, cell therapies – UCLA Newsroom

UCLA has received a $7.3 million grant from the National Institutes of Health to build a state-of-the-art facility in which to produce gene and cell therapies aimed at treating a host of illnesses and conditions.

The new 13,000-square-foot facility, to be constructed in UCLAs Center for the Health Sciences, will provide a highly regulated environment with features such as systems to manage air flow and filtering, laboratory spaces and bioreactors. The new facility is expected to be ready for use in 2023.

This grant provides critical funds to build a facility that will enable the development of a new generation of cellular therapies for cancer and other deadly diseases, said Dr. AntoniRibas, a UCLA professor of medicine and director of the Parker Institute for Cancer Immunotherapy Center at UCLA.

The new facility will be built according to U.S. Food and Drug Administrationgood manufacturing practices, a set of guidelines intended to ensure that facilities producing products for human use are built to maximize safety and effectiveness, and to reduce the risk for contamination.

It will replace a facility in UCLAs Factor Building that UCLA scientists currently use for similar research. But that space, which was put together by combining existing research laboratories, lacks the capacity to process certain cells and handle other bioengineered products, and it cannot accommodate the growing number of UCLA scientists pursuing research on gene and cell therapies, said Dr. Stephen Smale, vice dean for research at the David Geffen School of Medicine at UCLA and principal investigator of the NIH grant.

The new facility will be larger, so it will be able to support more projects simultaneously, and its design will allow a smooth flow of products into and out of the facility, Smale said. The larger number of rooms is really important because even when a single therapy is being tested, cells from each patient need to be processed in their own room.

Dr. Eric Esrailian, chief of theUCLA Vatche and Tamar Manoukian Division of Digestive Diseases, is helping to lead the expansion of UCLAs immunology and immunotherapy efforts. It will be a cornerstone for UCLAs commitments to building on existing strengths in the areas of immunology and immunotherapy and expanding toward the creation of a transformational institute in these fields, he said.

Despite the shortcomings of the current space, UCLA researchers have still produced groundbreaking work in it. These include tumor-targeting therapies developed by Ribas, Dr. Donald Kohn, Dr. Linda Liau, and other UCLA researchers.

Ribas, Kohn and Liau are also members of theUCLA Jonsson Comprehensive Cancer Centerand theUCLA Broad Stem Cell Research Center. Kohn is a distinguished professor of microbiology, immunology and molecular genetics and Liau is chair of UCLAs department of neurosurgery.

Kohn, who alsodeveloped a cure for bubble baby syndrome,said he will welcome the new facility because of its increased capacity for researchers to pursue treatments and cures that could significantly improve the health and quality of life of so many people. For instance, it will have the capacity to produce large batches of viral vectors microbes that make it possible to introduce potentially curative genes into cells for gene therapy studies.

This new facility will allow the innovative cell and gene therapies pioneered at UCLA to be available to a wider number of patients and accelerate the development of novel cures, said Kohn, whose work has also led to an experimental stem cell gene therapy for sickle cell disease that is showing promising early results in clinical trials.

Liau, a neuro-oncologist, said the new facility will enable researchers to create personalized vaccines and cell therapies for a much larger number of patients.

In the current facility, we are only able to enroll one patient at a time in our cell therapy trials, so many eligible patients have had to be turned away, Liau said.With greater capacity to manufacture gene and cell therapy products that meet FDA good manufacturing practice standards, this new UCLA facility will really allow us to further innovate and accelerate our translational research toward a cure for brain cancer.

Originally posted here:

UCLA receives $7.3 million grant to build state-of-the-art facility for developing gene, cell therapies - UCLA Newsroom

Celyad Oncology Provides Updates on Allogeneic and Autologous CAR T Programs at 62nd ASH Annual Meeting and Exposition – GlobeNewswire

MONT-SAINT-GUIBERT, Belgium, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced updates from the companys shRNA-based anti-B cell maturation antigen (BCMA) allogeneic CAR T candidate, CYAD-211, and autologous NKG2D receptor-based CAR T candidates, CYAD-01 and CYAD-02. These updates were virtually presented at the 62ndAmerican Society of Hematology (ASH) Annual Meeting and Exposition, held from December 5-8, 2020.

"The recent announcement of the dosing of our first patient with CYAD-211 in the IMMUNICY-1 trial was a major milestone for the organization as we continue to strategically focus on next-generation allogeneic CAR T cell therapies underpinned by our innovative shRNA technology platform that we took from concept to clinic in just two years," said Filippo Petti, Chief Executive Officer of Celyad Oncology. "With IMMUNICY-1, we're not only looking to offer patients with refractory multiple myeloma an option where few exist, but also to use this as an opportunity to validate the use of our shRNA platform as a novel allogeneic technology in what we believe could greatly expand our potential to develop best-in-class, off-the-shelf CAR T cell therapies.

Mr. Petti added, While we are disappointed by the latest update from the Phase 1 THINK trial for CYAD-01, we are encouraged by the initial clinical results from our next-generation CYAD-02 candidate for the treatment of patients with relapsed or refractory AML and MDS and look forward to future updates from the CYCLE-1 trial. With greater perspective on our autologous programs, the organization will remain steadfast in our commitment to patients with cancer by continuing to concentrate on the discovery and development of novel, allogeneic CAR T candidates.

CYAD-211 and IMMUNICY-1 Phase 1 Trial Update

Background

Preclinical Results

Study Design

Next Steps

CYAD-01 and THINK Phase 1 Trial Update

Background

Latest Clinical Data

Next Steps

CYAD-02 and CYCLE-1 Phase 1 Trial Update

Background

Preliminary Clinical Data

Next Steps

Conference Call and Webcast Details

Celyad Oncology will host a conference call to discuss the update from ASH on Monday, December 7, 2020 at 1 p.m. CET / 7 a.m. ET. The conference call can be accessed through the following numbers:

United States: +1 877 407 9716International: +1 201 493 6779

The conference call will be webcast live and can be accessed here. The event will also be archived and available on the Events section of the companys website. Please visit the website several minutes prior to the start of the broadcast to ensure adequate time for registration to the webcast.

About CYAD-211

CYAD-211 is an investigational, short hairpin RNA (shRNA)-based allogeneic CAR T candidate for the treatment of relapsed or refractory multiple myeloma (r/r MM). CYAD-211 is engineered to co-express a BCMA targeting chimeric antigen receptor and a single shRNA, which interferes with the expression of the CD3 component of the T cell receptor (TCR) complex. In July 2020, Celyad Oncology announced FDA Clearance of its IND application for CYAD-211.

About CYAD-01

CYAD-01 is an investigational CAR T therapy in which a patient's T cells are engineered to express a chimeric antigen receptor (CAR) based on NKG2D, a receptor expressed on natural killer (NK) cells that binds to eight stress-induced ligands expressed on tumor cells.

About CYAD-02

CYAD-02 is an investigational CAR T therapy that engineers an all-in-one vector approach in patients T cells to express both (i) the NKG2D chimeric antigen receptor (CAR), a receptor expressed on natural killer cells that binds to eight stress-induced ligands expressed on tumor cells, and (ii) short hairpin RNA (shRNA) SMARTvector technology licensed from Horizon Discovery to knockdown the expression of NKG2D ligands MICA and MICB on the CAR T cells. In preclinical models, shRNA-mediated knockdown of MICA and MICB expression on NKG2D CAR T cells has shown enhanced in vitro expansion, as well as enhanced in vivo engraftment and persistence, of the CAR T cells, as compared to first-generation NKG2D receptor based CAR T cells.

About Celyad Oncology

Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit http://www.celyad.com.

Forward-looking statements

This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include statements regarding: the clinical and preclinical activity of CYAD-02 and CYAD-211. Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risk and uncertainty include the duration and severity of the COVID-19 pandemic and government measures implemented in response thereto. A further list and description of these risks, uncertainties and other risks can be found in Celyad Oncologys U.S. Securities and Exchange Commission (SEC) filings and reports, including in its Annual Report on Form 20-F filed with the SEC on March 25, 2020 and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncologys actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

Investor and Media Contacts:

Sara ZelkovicCommunications & Investor Relations DirectorCelyad Oncology investors@celyad.com

Daniel FerryManaging DirectorLifeSci Advisors, LLCdaniel@lifesciadvisors.com

Source: Celyad Oncology SA

See the original post here:

Celyad Oncology Provides Updates on Allogeneic and Autologous CAR T Programs at 62nd ASH Annual Meeting and Exposition - GlobeNewswire

Evolving Standards and Heated Debates in the Treatment of Newly Diagnosed Multiple Myeloma – Curetoday.com

Over the past decade or so, the wealth of treatment options in newly diagnosed multiple myeloma (MM) has given patients a wider variety of possibilities. Coupled with rapidly evolving new standards in care, this can sometimes lead to confusion. But according to Dr. Clifton Mo, director of autologous stem cell transplantation for multiple myeloma at Dana-Farber Cancer Institute, that only means that the treatments are improving.

As anyone who's sought second or third opinions between different multiple myeloma centers can probably attest, you don't always walk out of the center with the same recommendation as the one before, said Mo. And what I tell my patients is, I understand that that can be somewhat disconcerting.

At CUREs Educated Patient Multiple Myeloma Summit, Mo spoke about how the treatment landscape of newly diagnosed MM has evolved, from single-agent chemotherapy to highly effective combinations that are continuously being examined and fine-tuned to offer patients the best outcomes.

As Mo explained, in the mid-1990s, the standard of care for this patient population was high-dose melphalan chemotherapy with autologous stem cell transplant. This plan was based on the results of two large studies that found a significant increase in overall survival between patients who were able to proceed to transplant with early high-dose melphalan compared with those who received only standard chemotherapy.

Then, after the development and approval of novel agent Velcade (bortezomib) in 2003, a new era of combined novel agent treatment began, with the most notable pair being the duo of Velcade and Revlimid (lenalidomide). It was found that the combination of Revlimid with the proteasome inhibitor, Velcade, was very synergistic, and was much more efficacious than single-agent novel therapy alone, Mo explained.

This combination led to further study, such as the 2012 landmark SWOG S0777 study comparing RVd (Revlimid, Velcade and dexamethasone) to single-agent Revlimid in patients without an immediate indication for stem cell transplant. In this study, patients treated with the triplet-induction regimen saw a 29% survival advantage compared with the single-agent group, leading to a new standard of care in MM and, as Mo explains, setting the stage for the current era of treatment.

But the introduction of Kyprolis (carfilzomib), a second-generation proteasome inhibitor similar to Velcade, set the stage for one of the first great debates in the treatment of newly diagnosed MM, said Mo.

First approved in the relapsed refractory setting, Kyprolis was found to be a potent and promising drug. But researchers were then compelled to determine which was better: RVd or KRd (Kyprolis, Revlimid and dexamethasone)?

This is arguably one of the biggest debates within the multiple myeloma community, Mo noted. While RVd demonstrated a 29% reduction in all-cause mortality compared with Revlimid alone in the SWOG-0777 study, researchers saw an impressive benefit of KRd compared with Revlimid alone in the relapsed and refractory setting thanks to the ASPIRE trial. Encouraging progression-free survival rates were also seen in high-risk patients treated with KRd.

However, each treatment comes with its own side effects that need to be taken into consideration. What we've known for a long time is that these two drugs have significant differences in terms of their toxicities and risks, said Mo. With Velcade, peripheral neuropathy is a common, though rarely dangerous. However, Kyprolis was shown to cause cardiotoxicity in less than 10% of patients, which, while uncommon, is also potentially very dangerous.

The debate between these two treatments continued mostly because there was no head-to-head data comparing the two in the newly diagnosed setting until several months ago, when results of the ENDURANCE (E1A11) phase 3 trial were presented. And while the study found that KRd was not more effective than Revlimid which remains the standard of care in this population some critics noted that RVd is not a better choice than KRd, especially given the toxicities associated with each, and that the trial design was flawed.

Mo, however, believes that both are still solid options. I'm going to hedge and say that they are still both within the realm of standard of care, and both acceptable induction regimens for newly diagnosed patients who are transplant eligible. (Because) it's myeloma. So of course, it's not straightforward, he said.

In my opinion, the educated patient may actually know best, so as long as the patient is aware of data, aware of the very real differences between toxicities and risks.

Another debate in the treatment of newly diagnosed myeloma involves when to perform autologous stem cell transplant. While this debate still continues, with studies evaluating early versus delayed transplant, Mo uses a military analogy to explain: I look at this debate as a choice between essentially using the big guns up front, versus low intensity warfare.

Lastly, Mo examined the debates that exist between the safety and efficacy of triplet therapy versus quad-induction therapy, which combines one of the standard triplets with a CD38 antibody, usually Darzalex (daratumumab). On the one hand, we have triplets, and we know that they are highly efficacious. They're essentially overall very well tolerated. They're lower risk than the quads in terms of risk of infection and other toxicities, they have a proven survival advantage and again, the elephant in the room, they are less expensive, said Mo. But with a depth of response of less than 50%, quads have been found to have unprecedented depths of response, albeit with a potentially greater risk of toxicity.

Ultimately, Mo noted, these debates and others in the MM community continue, with more trials looking at the pros and cons of every variety of combination, all with the goal of providing patients with the safest and most effective treatments.

For more news on cancer updates, research and education, dont forget tosubscribe to CUREs newsletters here.

More here:

Evolving Standards and Heated Debates in the Treatment of Newly Diagnosed Multiple Myeloma - Curetoday.com

Cloning – Wikipedia

Process of producing genetically identical individuals of an organism

Cloning is the process of producing individuals with identical or virtually identical DNA, either naturally or artificially. In nature, many organisms produce clones through asexual reproduction. Cloning in biotechnology refers to the process of creating clones of organisms or copies of cells or DNA fragments (molecular cloning).

The term clone, coined by Herbert J. Webber, is derived from the Ancient Greek word kln, "twig", referring to the process whereby a new plant can be created from a twig. In botany, the term lusus was traditionally used.[1] In horticulture, the spelling clon was used until the twentieth century; the final e came into use to indicate the vowel is a "long o" instead of a "short o".[2][3] Since the term entered the popular lexicon in a more general context, the spelling clone has been used exclusively.

Cloning is a natural form of reproduction that has allowed life forms to spread for hundreds of millions of years. It is the reproduction method used by plants, fungi, and bacteria, and is also the way that clonal colonies reproduce themselves.[4][5] Examples of these organisms include blueberry plants, hazel trees, the Pando trees,[6][7] the Kentucky coffeetree, Myrica, and the American sweetgum.

Molecular cloning refers to the process of making multiple molecules. Cloning is commonly used to amplify DNA fragments containing whole genes, but it can also be used to amplify any DNA sequence such as promoters, non-coding sequences and randomly fragmented DNA. It is used in a wide array of biological experiments and practical applications ranging from genetic fingerprinting to large scale protein production. Occasionally, the term cloning is misleadingly used to refer to the identification of the chromosomal location of a gene associated with a particular phenotype of interest, such as in positional cloning. In practice, localization of the gene to a chromosome or genomic region does not necessarily enable one to isolate or amplify the relevant genomic sequence. To amplify any DNA sequence in a living organism, that sequence must be linked to an origin of replication, which is a sequence of DNA capable of directing the propagation of itself and any linked sequence. However, a number of other features are needed, and a variety of specialised cloning vectors (small piece of DNA into which a foreign DNA fragment can be inserted) exist that allow protein production, affinity tagging, single stranded RNA or DNA production and a host of other molecular biology tools.

Cloning of any DNA fragment essentially involves four steps[8]

Although these steps are invariable among cloning procedures a number of alternative routes can be selected; these are summarized as a cloning strategy.

Initially, the DNA of interest needs to be isolated to provide a DNA segment of suitable size. Subsequently, a ligation procedure is used where the amplified fragment is inserted into a vector (piece of DNA). The vector (which is frequently circular) is linearised using restriction enzymes, and incubated with the fragment of interest under appropriate conditions with an enzyme called DNA ligase. Following ligation the vector with the insert of interest is transfected into cells. A number of alternative techniques are available, such as chemical sensitisation of cells, electroporation, optical injection and biolistics. Finally, the transfected cells are cultured. As the aforementioned procedures are of particularly low efficiency, there is a need to identify the cells that have been successfully transfected with the vector construct containing the desired insertion sequence in the required orientation. Modern cloning vectors include selectable antibiotic resistance markers, which allow only cells in which the vector has been transfected, to grow. Additionally, the cloning vectors may contain colour selection markers, which provide blue/white screening (alpha-factor complementation) on X-gal medium. Nevertheless, these selection steps do not absolutely guarantee that the DNA insert is present in the cells obtained. Further investigation of the resulting colonies must be required to confirm that cloning was successful. This may be accomplished by means of PCR, restriction fragment analysis and/or DNA sequencing.

Cloning a cell means to derive a population of cells from a single cell. In the case of unicellular organisms such as bacteria and yeast, this process is remarkably simple and essentially only requires the inoculation of the appropriate medium. However, in the case of cell cultures from multi-cellular organisms, cell cloning is an arduous task as these cells will not readily grow in standard media.

A useful tissue culture technique used to clone distinct lineages of cell lines involves the use of cloning rings (cylinders).[9] In this technique a single-cell suspension of cells that have been exposed to a mutagenic agent or drug used to drive selection is plated at high dilution to create isolated colonies, each arising from a single and potentially clonal distinct cell. At an early growth stage when colonies consist of only a few cells, sterile polystyrene rings (cloning rings), which have been dipped in grease, are placed over an individual colony and a small amount of trypsin is added. Cloned cells are collected from inside the ring and transferred to a new vessel for further growth.

Somatic-cell nuclear transfer, popularly known as SCNT, can also be used to create embryos for research or therapeutic purposes. The most likely purpose for this is to produce embryos for use in stem cell research. This process is also called "research cloning" or "therapeutic cloning". The goal is not to create cloned human beings (called "reproductive cloning"), but rather to harvest stem cells that can be used to study human development and to potentially treat disease. While a clonal human blastocyst has been created, stem cell lines are yet to be isolated from a clonal source.[10]

Therapeutic cloning is achieved by creating embryonic stem cells in the hopes of treating diseases such as diabetes and Alzheimer's. The process begins by removing the nucleus (containing the DNA) from an egg cell and inserting a nucleus from the adult cell to be cloned.[11] In the case of someone with Alzheimer's disease, the nucleus from a skin cell of that patient is placed into an empty egg. The reprogrammed cell begins to develop into an embryo because the egg reacts with the transferred nucleus. The embryo will become genetically identical to the patient.[11] The embryo will then form a blastocyst which has the potential to form/become any cell in the body.[12]

The reason why SCNT is used for cloning is because somatic cells can be easily acquired and cultured in the lab. This process can either add or delete specific genomes of farm animals. A key point to remember is that cloning is achieved when the oocyte maintains its normal functions and instead of using sperm and egg genomes to replicate, the oocyte is inserted into the donor's somatic cell nucleus.[13] The oocyte will react on the somatic cell nucleus, the same way it would on sperm cells.[13]

The process of cloning a particular farm animal using SCNT is relatively the same for all animals. The first step is to collect the somatic cells from the animal that will be cloned. The somatic cells could be used immediately or stored in the laboratory for later use.[13] The hardest part of SCNT is removing maternal DNA from an oocyte at metaphase II. Once this has been done, the somatic nucleus can be inserted into an egg cytoplasm.[13] This creates a one-cell embryo. The grouped somatic cell and egg cytoplasm are then introduced to an electrical current.[13] This energy will hopefully allow the cloned embryo to begin development. The successfully developed embryos are then placed in surrogate recipients, such as a cow or sheep in the case of farm animals.[13]

SCNT is seen as a good method for producing agriculture animals for food consumption. It successfully cloned sheep, cattle, goats, and pigs. Another benefit is SCNT is seen as a solution to clone endangered species that are on the verge of going extinct.[13] However, stresses placed on both the egg cell and the introduced nucleus can be enormous, which led to a high loss in resulting cells in early research. For example, the cloned sheep Dolly was born after 277 eggs were used for SCNT, which created 29 viable embryos. Only three of these embryos survived until birth, and only one survived to adulthood.[14] As the procedure could not be automated, and had to be performed manually under a microscope, SCNT was very resource intensive. The biochemistry involved in reprogramming the differentiated somatic cell nucleus and activating the recipient egg was also far from being well understood. However, by 2014 researchers were reporting cloning success rates of seven to eight out of ten[15] and in 2016, a Korean Company Sooam Biotech was reported to be producing 500 cloned embryos per day.[16]

In SCNT, not all of the donor cell's genetic information is transferred, as the donor cell's mitochondria that contain their own mitochondrial DNA are left behind. The resulting hybrid cells retain those mitochondrial structures which originally belonged to the egg. As a consequence, clones such as Dolly that are born from SCNT are not perfect copies of the donor of the nucleus.

Organism cloning (also called reproductive cloning) refers to the procedure of creating a new multicellular organism, genetically identical to another. In essence this form of cloning is an asexual method of reproduction, where fertilization or inter-gamete contact does not take place. Asexual reproduction is a naturally occurring phenomenon in many species, including most plants and some insects. Scientists have made some major achievements with cloning, including the asexual reproduction of sheep and cows. There is a lot of ethical debate over whether or not cloning should be used. However, cloning, or asexual propagation,[17] has been common practice in the horticultural world for hundreds of years.

The term clone is used in horticulture to refer to descendants of a single plant which were produced by vegetative reproduction or apomixis. Many horticultural plant cultivars are clones, having been derived from a single individual, multiplied by some process other than sexual reproduction.[18] As an example, some European cultivars of grapes represent clones that have been propagated for over two millennia. Other examples are potato and banana.[19]

Grafting can be regarded as cloning, since all the shoots and branches coming from the graft are genetically a clone of a single individual, but this particular kind of cloning has not come under ethical scrutiny and is generally treated as an entirely different kind of operation.

Many trees, shrubs, vines, ferns and other herbaceous perennials form clonal colonies naturally. Parts of an individual plant may become detached by fragmentation and grow on to become separate clonal individuals. A common example is in the vegetative reproduction of moss and liverwort gametophyte clones by means of gemmae. Some vascular plants e.g. dandelion and certain viviparous grasses also form seeds asexually, termed apomixis, resulting in clonal populations of genetically identical individuals.

Clonal derivation exists in nature in some animal species and is referred to as parthenogenesis (reproduction of an organism by itself without a mate). This is an asexual form of reproduction that is only found in females of some insects, crustaceans, nematodes,[20] fish (for example the hammerhead shark[21]), and lizards including the Komodo dragon[21] and several whiptails. The growth and development occurs without fertilization by a male. In plants, parthenogenesis means the development of an embryo from an unfertilized egg cell, and is a component process of apomixis. In species that use the XY sex-determination system, the offspring will always be female. An example is the little fire ant (Wasmannia auropunctata), which is native to Central and South America but has spread throughout many tropical environments.

Artificial cloning of organisms may also be called reproductive cloning.

Hans Spemann, a German embryologist was awarded a Nobel Prize in Physiology or Medicine in 1935 for his discovery of the effect now known as embryonic induction, exercised by various parts of the embryo, that directs the development of groups of cells into particular tissues and organs. In 1924 he and his student, Hilde Mangold, were the first to perform somatic-cell nuclear transfer using amphibian embryos one of the first steps towards cloning.[22]

Reproductive cloning generally uses "somatic cell nuclear transfer" (SCNT) to create animals that are genetically identical. This process entails the transfer of a nucleus from a donor adult cell (somatic cell) to an egg from which the nucleus has been removed, or to a cell from a blastocyst from which the nucleus has been removed.[23] If the egg begins to divide normally it is transferred into the uterus of the surrogate mother. Such clones are not strictly identical since the somatic cells may contain mutations in their nuclear DNA. Additionally, the mitochondria in the cytoplasm also contains DNA and during SCNT this mitochondrial DNA is wholly from the cytoplasmic donor's egg, thus the mitochondrial genome is not the same as that of the nucleus donor cell from which it was produced. This may have important implications for cross-species nuclear transfer in which nuclear-mitochondrial incompatibilities may lead to death.

Artificial embryo splitting or embryo twinning, a technique that creates monozygotic twins from a single embryo, is not considered in the same fashion as other methods of cloning. During that procedure, a donor embryo is split in two distinct embryos, that can then be transferred via embryo transfer. It is optimally performed at the 6- to 8-cell stage, where it can be used as an expansion of IVF to increase the number of available embryos.[24] If both embryos are successful, it gives rise to monozygotic (identical) twins.

Dolly, a Finn-Dorset ewe, was the first mammal to have been successfully cloned from an adult somatic cell. Dolly was formed by taking a cell from the udder of her 6-year-old biological mother.[25] Dolly's embryo was created by taking the cell and inserting it into a sheep ovum. It took 434 attempts before an embryo was successful.[26] The embryo was then placed inside a female sheep that went through a normal pregnancy.[27] She was cloned at the Roslin Institute in Scotland by British scientists Sir Ian Wilmut and Keith Campbell and lived there from her birth in 1996 until her death in 2003 when she was six. She was born on 5 July 1996 but not announced to the world until 22 February 1997.[28] Her stuffed remains were placed at Edinburgh's Royal Museum, part of the National Museums of Scotland.[29]

Dolly was publicly significant because the effort showed that genetic material from a specific adult cell, designed to express only a distinct subset of its genes, can be redesigned to grow an entirely new organism. Before this demonstration, it had been shown by John Gurdon that nuclei from differentiated cells could give rise to an entire organism after transplantation into an enucleated egg.[30] However, this concept was not yet demonstrated in a mammalian system.

The first mammalian cloning (resulting in Dolly the sheep) had a success rate of 29 embryos per 277 fertilized eggs, which produced three lambs at birth, one of which lived. In a bovine experiment involving 70 cloned calves, one-third of the calves died quite young. The first successfully cloned horse, Prometea, took 814 attempts. Notably, although the first[clarification needed] clones were frogs, no adult cloned frog has yet been produced from a somatic adult nucleus donor cell.

There were early claims that Dolly the sheep had pathologies resembling accelerated aging. Scientists speculated that Dolly's death in 2003 was related to the shortening of telomeres, DNA-protein complexes that protect the end of linear chromosomes. However, other researchers, including Ian Wilmut who led the team that successfully cloned Dolly, argue that Dolly's early death due to respiratory infection was unrelated to problems with the cloning process. This idea that the nuclei have not irreversibly aged was shown in 2013 to be true for mice.[31]

Dolly was named after performer Dolly Parton because the cells cloned to make her were from a mammary gland cell, and Parton is known for her ample cleavage.[32]

The modern cloning techniques involving nuclear transfer have been successfully performed on several species. Notable experiments include:

Human cloning is the creation of a genetically identical copy of a human. The term is generally used to refer to artificial human cloning, which is the reproduction of human cells and tissues. It does not refer to the natural conception and delivery of identical twins. The possibility of human cloning has raised controversies. These ethical concerns have prompted several nations to pass legislation regarding human cloning and its legality. As of right now, scientists have no intention of trying to clone people and they believe their results should spark a wider discussion about the laws and regulations the world needs to regulate cloning.[66]

Two commonly discussed types of theoretical human cloning are therapeutic cloning and reproductive cloning. Therapeutic cloning would involve cloning cells from a human for use in medicine and transplants, and is an active area of research, but is not in medical practice anywhere in the world, as of 2020[update]. Two common methods of therapeutic cloning that are being researched are somatic-cell nuclear transfer and, more recently, pluripotent stem cell induction. Reproductive cloning would involve making an entire cloned human, instead of just specific cells or tissues.[67]

There are a variety of ethical positions regarding the possibilities of cloning, especially human cloning. While many of these views are religious in origin, the questions raised by cloning are faced by secular perspectives as well. Perspectives on human cloning are theoretical, as human therapeutic and reproductive cloning are not commercially used; animals are currently cloned in laboratories and in livestock production.

Advocates support development of therapeutic cloning in order to generate tissues and whole organs to treat patients who otherwise cannot obtain transplants,[68] to avoid the need for immunosuppressive drugs,[67] and to stave off the effects of aging.[69] Advocates for reproductive cloning believe that parents who cannot otherwise procreate should have access to the technology.[70]

Opponents of cloning have concerns that technology is not yet developed enough to be safe[71] and that it could be prone to abuse (leading to the generation of humans from whom organs and tissues would be harvested),[72][73] as well as concerns about how cloned individuals could integrate with families and with society at large.[74][75]

Religious groups are divided, with some opposing the technology as usurping "God's place" and, to the extent embryos are used, destroying a human life; others support therapeutic cloning's potential life-saving benefits.[76][77]

Cloning of animals is opposed by animal-groups due to the number of cloned animals that suffer from malformations before they die, and while food from cloned animals has been approved by the US FDA,[78][79] its use is opposed by groups concerned about food safety.[80][81]

Cloning, or more precisely, the reconstruction of functional DNA from extinct species has, for decades, been a dream. Possible implications of this were dramatized in the 1984 novel Carnosaur and the 1990 novel Jurassic Park.[82][83] The best current cloning techniques have an average success rate of 9.4 percent[84] (and as high as 25 percent[31]) when working with familiar species such as mice,[note 1] while cloning wild animals is usually less than 1 percent successful.[87] Several tissue banks have come into existence, including the "Frozen Zoo" at the San Diego Zoo, to store frozen tissue from the world's rarest and most endangered species.[82][88][89]

In 2001, a cow named Bessie gave birth to a cloned Asian gaur, an endangered species, but the calf died after two days. In 2003, a banteng was successfully cloned, followed by three African wildcats from a thawed frozen embryo. These successes provided hope that similar techniques (using surrogate mothers of another species) might be used to clone extinct species. Anticipating this possibility, tissue samples from the last bucardo (Pyrenean ibex) were frozen in liquid nitrogen immediately after it died in 2000. Researchers are also considering cloning endangered species such as the giant panda and cheetah.[90][91][92][93]

In 2002, geneticists at the Australian Museum announced that they had replicated DNA of the thylacine (Tasmanian tiger), at the time extinct for about 65 years, using polymerase chain reaction.[94] However, on 15 February 2005 the museum announced that it was stopping the project after tests showed the specimens' DNA had been too badly degraded by the (ethanol) preservative. On 15 May 2005 it was announced that the thylacine project would be revived, with new participation from researchers in New South Wales and Victoria.[95]

In 2003, for the first time, an extinct animal, the Pyrenean ibex mentioned above was cloned, at the Centre of Food Technology and Research of Aragon, using the preserved frozen cell nucleus of the skin samples from 2001 and domestic goat egg-cells. The ibex died shortly after birth due to physical defects in its lungs.[96]

One of the most anticipated targets for cloning was once the woolly mammoth, but attempts to extract DNA from frozen mammoths have been unsuccessful, though a joint Russo-Japanese team is currently working toward this goal. In January 2011, it was reported by Yomiuri Shimbun that a team of scientists headed by Akira Iritani of Kyoto University had built upon research by Dr. Wakayama, saying that they will extract DNA from a mammoth carcass that had been preserved in a Russian laboratory and insert it into the egg cells of an African elephant in hopes of producing a mammoth embryo. The researchers said they hoped to produce a baby mammoth within six years.[97][98] It was noted, however that the result, if possible, would be an elephant-mammoth hybrid rather than a true mammoth.[99] Another problem is the survival of the reconstructed mammoth: ruminants rely on a symbiosis with specific microbiota in their stomachs for digestion.[99]

Scientists at the University of Newcastle and University of New South Wales announced in March 2013 that the very recently extinct gastric-brooding frog would be the subject of a cloning attempt to resurrect the species.[100]

Many such "De-extinction" projects are described in the Long Now Foundation's Revive and Restore Project.[101]

After an eight-year project involving the use of a pioneering cloning technique, Japanese researchers created 25 generations of healthy cloned mice with normal lifespans, demonstrating that clones are not intrinsically shorter-lived than naturally born animals.[31][102] Other sources have noted that the offspring of clones tend to be healthier than the original clones and indistinguishable from animals produced naturally.[103]

Dolly the sheep was cloned from a six-year old cell sample from a mammary gland. Because of this, some posited she may have aged more quickly than other naturally born animals, as she died relatively early for a sheep at the age of six. Ultimately, her death was attributed to a respiratory illness, and the "advanced aging" theory is disputed.[104][dubious discuss]

A detailed study released in 2016 and less detailed studies by others suggest that once cloned animals get past the first month or two of life they are generally healthy. However, early pregnancy loss and neonatal losses are still greater with cloning than natural conception or assisted reproduction (IVF). Current research is attempting to overcome these problems.[32]

Discussion of cloning in the popular media often presents the subject negatively. In an article in the 8 November 1993 article of Time, cloning was portrayed in a negative way, modifying Michelangelo's Creation of Adam to depict Adam with five identical hands.[105] Newsweek's 10 March 1997 issue also critiqued the ethics of human cloning, and included a graphic depicting identical babies in beakers.[106]

The concept of cloning, particularly human cloning, has featured a wide variety of science fiction works. An early fictional depiction of cloning is Bokanovsky's Process which features in Aldous Huxley's 1931 dystopian novel Brave New World. The process is applied to fertilized human eggs in vitro, causing them to split into identical genetic copies of the original.[107][108] Following renewed interest in cloning in the 1950s, the subject was explored further in works such as Poul Anderson's 1953 story UN-Man, which describes a technology called "exogenesis", and Gordon Rattray Taylor's book The Biological Time Bomb, which popularised the term "cloning" in 1963.[109]

Cloning is a recurring theme in a number of contemporary science fiction films, ranging from action films such as Jurassic Park (1993), Alien Resurrection (1997), The 6th Day (2000), Resident Evil (2002), Star Wars: Episode II Attack of the Clones (2002), The Island (2005) and Moon (2009) to comedies such as Woody Allen's 1973 film Sleeper.[110]

The process of cloning is represented variously in fiction. Many works depict the artificial creation of humans by a method of growing cells from a tissue or DNA sample; the replication may be instantaneous, or take place through slow growth of human embryos in artificial wombs. In the long-running British television series Doctor Who, the Fourth Doctor and his companion Leela were cloned in a matter of seconds from DNA samples ("The Invisible Enemy", 1977) and then in an apparent homage to the 1966 film Fantastic Voyage shrunk to microscopic size in order to enter the Doctor's body to combat an alien virus. The clones in this story are short-lived, and can only survive a matter of minutes before they expire.[111] Science fiction films such as The Matrix and Star Wars: Episode II Attack of the Clones have featured scenes of human foetuses being cultured on an industrial scale in mechanical tanks.[112]

Cloning humans from body parts is also a common theme in science fiction. Cloning features strongly among the science fiction conventions parodied in Woody Allen's Sleeper, the plot of which centres around an attempt to clone an assassinated dictator from his disembodied nose.[113] In the 2008 Doctor Who story "Journey's End", a duplicate version of the Tenth Doctor spontaneously grows from his severed hand, which had been cut off in a sword fight during an earlier episode.[114]

After the death of her beloved 14-year-old Coton de Tulear named Samantha in late 2017, Barbra Streisand announced that she had cloned the dog, and was now "waiting for [the two cloned pups] to get older so [she] can see if they have [Samantha's] brown eyes and her seriousness".[115] The operation cost $50,000 through the pet cloning company ViaGen.[116]

Science fiction has used cloning, most commonly and specifically human cloning, to raise the controversial questions of identity.[117][118] A Number is a 2002 play by English playwright Caryl Churchill which addresses the subject of human cloning and identity, especially nature and nurture. The story, set in the near future, is structured around the conflict between a father (Salter) and his sons (Bernard 1, Bernard 2, and Michael Black) two of whom are clones of the first one. A Number was adapted by Caryl Churchill for television, in a co-production between the BBC and HBO Films.[119]

In 2012, a Japanese television series named "Bunshin" was created. The story's main character, Mariko, is a woman studying child welfare in Hokkaido. She grew up always doubtful about the love from her mother, who looked nothing like her and who died nine years before. One day, she finds some of her mother's belongings at a relative's house, and heads to Tokyo to seek out the truth behind her birth. She later discovered that she was a clone.[120]

In the 2013 television series Orphan Black, cloning is used as a scientific study on the behavioral adaptation of the clones.[121] In a similar vein, the book The Double by Nobel Prize winner Jos Saramago explores the emotional experience of a man who discovers that he is a clone.[122]

Cloning has been used in fiction as a way of recreating historical figures. In the 1976 Ira Levin novel The Boys from Brazil and its 1978 film adaptation, Josef Mengele uses cloning to create copies of Adolf Hitler.[123]

In Michael Crichton's 1990 novel Jurassic Park, which spawned a series of Jurassic Park feature films, a bioengineering company develops a technique to resurrect extinct species of dinosaurs by creating cloned creatures using DNA extracted from fossils. The cloned dinosaurs are used to populate the Jurassic Park wildlife park for the entertainment of visitors. The scheme goes disastrously wrong when the dinosaurs escape their enclosures. Despite being selectively cloned as females to prevent them from breeding, the dinosaurs develop the ability to reproduce through parthenogenesis.[124]

The use of cloning for military purposes has also been explored in several fictional works. In Doctor Who, an alien race of armour-clad, warlike beings called Sontarans was introduced in the 1973 serial "The Time Warrior". Sontarans are depicted as squat, bald creatures who have been genetically engineered for combat. Their weak spot is a "probic vent", a small socket at the back of their neck which is associated with the cloning process.[125] The concept of cloned soldiers being bred for combat was revisited in "The Doctor's Daughter" (2008), when the Doctor's DNA is used to create a female warrior called Jenny.[126]

The 1977 film Star Wars was set against the backdrop of a historical conflict called the Clone Wars. The events of this war were not fully explored until the prequel films Attack of the Clones (2002) and Revenge of the Sith (2005), which depict a space war waged by a massive army of heavily armoured clone troopers that leads to the foundation of the Galactic Empire. Cloned soldiers are "manufactured" on an industrial scale, genetically conditioned for obedience and combat effectiveness. It is also revealed that the popular character Boba Fett originated as a clone of Jango Fett, a mercenary who served as the genetic template for the clone troopers.[127][128]

A recurring sub-theme of cloning fiction is the use of clones as a supply of organs for transplantation. The 2005 Kazuo Ishiguro novel Never Let Me Go and the 2010 film adaption[129] are set in an alternate history in which cloned humans are created for the sole purpose of providing organ donations to naturally born humans, despite the fact that they are fully sentient and self-aware. The 2005 film The Island[130] revolves around a similar plot, with the exception that the clones are unaware of the reason for their existence.

The exploitation of human clones for dangerous and undesirable work was examined in the 2009 British science fiction film Moon.[131] In the futuristic novel Cloud Atlas and subsequent film, one of the story lines focuses on a genetically-engineered fabricant clone named Sonmi~451, one of millions raised in an artificial "wombtank," destined to serve from birth. She is one of thousands created for manual and emotional labor; Sonmi herself works as a server in a restaurant. She later discovers that the sole source of food for clones, called 'Soap', is manufactured from the clones themselves.[132]

In the film Us, at some point prior to the 1980s, the US Government creates clones of every citizen of the United States with the intention of using them to control their original counterparts, akin to voodoo dolls. This fails, as they were able to copy bodies, but unable to copy the souls of those they cloned. The project is abandoned and the clones are trapped exactly mirroring their above-ground counterparts' actions for generations. In the present day, the clones launch a surprise attack and manage to complete a mass-genocide of their unaware counterparts.[133][134]

In the Anime, Manga and Light Novels of A Certain Magical Index and A Certain Scientific Railgun, one of the espers named Mikoto Misaka's DNA was harvested unknowingly, creating 12,000 exact but not equally powerful clones for an experiment. They were used as target practice by Accelerator, just to level up, as killing the original multiple times is impossible. The experiment ended when Tma Kamij saved and foiled the experiment. The remaining clones have been dispersed everywhere in the world to conduct further experiments to expand their lifespans, save for at least 10 who remained in Academy City, and the last clone, who was not fully developed when the experiment stopped.

See the original post here:

Cloning - Wikipedia

Cloning | National Geographic Society

Cloning is a technique scientists use to make exact genetic copies of living things. Genes, cells, tissues, and even whole animals can all be cloned.

Some clones already exist in nature. Single-celled organisms like bacteria make exact copies of themselves each time they reproduce. In humans, identical twins are similar to clones. They share almost the exact same genes. Identical twins are created when a fertilized egg splits in two.

Scientists also make clones in the lab. They often clone genes in order to study and better understand them. To clone a gene, researchers take DNA from a living creature and insert it into a carrier like bacteria or yeast. Every time that carrier reproduces, a new copy of the gene is made.

Animals are cloned in one of two ways. The first is called embryo twinning. Scientists first split an embryo in half. Those two halves are then placed in a mothers uterus. Each part of the embryo develops into a unique animal, and the two animals share the same genes. The second method is called somatic cell nuclear transfer. Somatic cells are all the cells that make up an organism, but that are not sperm or egg cells. Sperm and egg cells contain only one set of chromosomes, and when they join during fertilization, the mothers chromosomes merge with the fathers. Somatic cells, on the other hand, already contain two full sets of chromosomes. To make a clone, scientists transfer the DNA from an animals somatic cell into an egg cell that has had its nucleus and DNA removed. The egg develops into an embryo that contains the same genes as the cell donor. Then the embryo is implanted into an adult females uterus to grow.

In 1996, Scottish scientists cloned the first animal, a sheep they named Dolly. She was cloned using an udder cell taken from an adult sheep. Since then, scientists have cloned cows, cats, deer, horses, and rabbits. They still have not cloned a human, though. In part, this is because it is difficult to produce a viable clone. In each attempt, there can be genetic mistakes that prevent the clone from surviving. It took scientists 276 attempts to get Dolly right. There are also ethical concerns about cloning a human being.

Researchers can use clones in many ways. An embryo made by cloning can be turned into a stem cell factory. Stem cells are an early form of cells that can grow into many different types of cells and tissues. Scientists can turn them into nerve cells to fix a damaged spinal cord or insulin-making cells to treat diabetes.

The cloning of animals has been used in a number of different applications. Animals have been cloned to have gene mutations that help scientists study diseases that develop in the animals. Livestock like cows and pigs have been cloned to produce more milk or meat. Clones can even resurrect a beloved pet that has died. In 2001, a cat named CC was the first pet to be created through cloning. Cloning might one day bring back extinct species like the woolly mammoth or giant panda.

Original post:

Cloning | National Geographic Society

cloning | Definition, Process, & Types | Britannica

Cloning, the process of generating a genetically identical copy of a cell or an organism. Cloning happens often in naturefor example, when a cell replicates itself asexually without any genetic alteration or recombination. Prokaryotic organisms (organisms lacking a cell nucleus) such as bacteria create genetically identical duplicates of themselves using binary fission or budding. In eukaryotic organisms (organisms possessing a cell nucleus) such as humans, all the cells that undergo mitosis, such as skin cells and cells lining the gastrointestinal tract, are clones; the only exceptions are gametes (eggs and sperm), which undergo meiosis and genetic recombination.

Top Questions

Cloning is the process of generating a genetically identical copy of acellor an organism.Cloning happens all the time in nature. In biomedical research, cloning is broadly defined to mean the duplication of any kind of biological material for scientific study, such as a piece ofDNAor an individual cell.

Therapeutic cloning enables the cultivation of stem cells that are genetically identical to a patient. This approach, by avoiding risk of rejection by theimmune system, has the potential to benefit many patients,including those affected byAlzheimer disease,diabetes, andspinal cordinjury.

The cloning of humans remains universally condemned, primarily for the associated psychological, social, and physiological risks. There are also concerns that cloning promoteseugenics, the idea that humanity could be improved through the selection of individuals possessing desired traits. There also exists controversy over theethicsof therapeutic and research cloning, which makes use of embryos that are otherwise discarded.

In biomedical research, cloning is broadly defined to mean the duplication of any kind of biological material for scientific study, such as a piece of DNA or an individual cell. For example, segments of DNA are replicated exponentially by a process known as polymerase chain reaction, or PCR, a technique that is used widely in basic biological research. The type of cloning that is the focus of much ethical controversy involves the generation of cloned embryos, particularly those of humans, which are genetically identical to the organisms from which they are derived, and the subsequent use of these embryos for research, therapeutic, or reproductive purposes.

Reproductive cloning was originally carried out by artificial twinning, or embryo splitting, which was first performed on a salamander embryo in the early 1900s by German embryologist Hans Spemann. Later, Spemann, who was awarded the Nobel Prize for Physiology or Medicine (1935) for his research on embryonic development, theorized about another cloning procedure known as nuclear transfer. This procedure was performed in 1952 by American scientists Robert W. Briggs and Thomas J. King, who used DNA from embryonic cells of the frog Rana pipiens to generate cloned tadpoles. In 1958 British biologist John Bertrand Gurdon successfully carried out nuclear transfer using DNA from adult intestinal cells of African clawed frogs (Xenopus laevis). Gurdon was awarded a share of the 2012 Nobel Prize in Physiology or Medicine for this breakthrough.

Overview of somatic cell nuclear transfer (SCNT). In 1996 the first clone of an adult mammal, a female sheep named Dolly, was born. Dolly was created using SCNT, a process that later became a cornerstone of stem cell research.

Advancements in the field of molecular biology led to the development of techniques that allowed scientists to manipulate cells and to detect chemical markers that signal changes within cells. With the advent of recombinant DNA technology in the 1970s, it became possible for scientists to create transgenic clonesclones with genomes containing pieces of DNA from other organisms. Beginning in the 1980s mammals such as sheep were cloned from early and partially differentiated embryonic cells. In 1996 British developmental biologist Ian Wilmut generated a cloned sheep, named Dolly, by means of nuclear transfer involving an enucleated embryo and a differentiated cell nucleus. This technique, which was later refined and became known as somatic cell nuclear transfer (SCNT), represented an extraordinary advance in the science of cloning, because it resulted in the creation of a genetically identical clone of an already grown sheep. It also indicated that it was possible for the DNA in differentiated somatic (body) cells to revert to an undifferentiated embryonic stage, thereby reestablishing pluripotencythe potential of an embryonic cell to grow into any one of the numerous different types of mature body cells that make up a complete organism. The realization that the DNA of somatic cells could be reprogrammed to a pluripotent state significantly impacted research into therapeutic cloning and the development of stem cell therapies.

Soon after the generation of Dolly, a number of other animals were cloned by SCNT, including pigs, goats, rats, mice, dogs, horses, and mules. Despite those successes, the birth of a viable SCNT primate clone would not come to fruition until 2018, and scientists used other cloning processes in the meantime. In 2001 a team of scientists cloned a rhesus monkey through a process called embryonic cell nuclear transfer, which is similar to SCNT except that it uses DNA from an undifferentiated embryo. In 2007 macaque monkey embryos were cloned by SCNT, but those clones lived only to the blastocyst stage of embryonic development. It was more than 10 years later, after improvements to SCNT had been made, that scientists announced the live birth of two clones of the crab-eating macaque (Macaca fascicularis), the first primate clones using the SCNT process. (SCNT has been carried out with very limited success in humans, in part because of problems with human egg cells resulting from the mothers age and environmental factors.)

The first cloned cat, named CC (or Copy Cat), was born on December 22, 2001, to her surrogate mom, Allie (pictured).

More:

cloning | Definition, Process, & Types | Britannica

Not Entirely in His DNA: Gilles Simon Criticizes Grigor Dimitrov for Cloning the Style of Ro … – EssentiallySports

French professional tennis player Gilles Simon seems quite fascinated with Roger Federer. Even when he doesnt want to talk about the Swiss Maestro, journalists find a way to ask him something about Federer. However, he respects the 20-time Grand Slam winner and has admitted earlier that Federer was his sons hero.

In a recent interview, there was a question about the former World No.3 Grigor Dimitrov. However, the interviewer phrased it in a manner that it also involved Federer. The question was whether Dimitrov had limited himself in his career by replicating Federer. To this, the Frenchman replied in affirmative.

Yes, began a confident Simon. Hes (Grigor Dimitrov) clearly a player who comes close in terms of fluidity of play.

It was clear that Simon felt that Dimitrov was quite close in cloning Roger Federers style. He further believed that it was something that was not doing any good for Dimitrov.

Read More: Gilles Simon racks up Roger Federer again in the debate on tennis role model

Simon further argued that Dimitrov was trying to do something that he simply couldnt do.

In the important moments, it can give up because, in reality, it is not entirely in his DNA, concluded the 35-year-old Simon.

He was blunt and didnt hesitate in saying that Federers style was not there in Dimitrovs DNA. He said that the player could try to copy it but it was futile as it would not help him in the longer run.

It was certain that Simon was criticizing Dimitrov. In a way, he even advised him not to do so in the future.

Both Dimitrov and Simon will begin the upcoming season at the Australian Open 2021. Joining them there will be none other than Roger Federer who will also make a comeback to tennis after a year.

Also Read: Gilles Simon slams French Tennis for wasting energy on replicating Roger Federer

Read the original here:

Not Entirely in His DNA: Gilles Simon Criticizes Grigor Dimitrov for Cloning the Style of Ro ... - EssentiallySports

Cloning Fact Sheet – Genome.gov

Reproductive cloning may enable researchers to make copies of animals with the potential benefits for the fields of medicine and agriculture.

For instance, the same Scottish researchers who cloned Dolly have cloned other sheep that have been genetically modified to produce milk that contains a human protein essential for blood clotting. The hope is that someday this protein can be purified from the milk and given to humans whose blood does not clot properly. Another possible use of cloned animals is for testing new drugs and treatment strategies. The great advantage of using cloned animals for drug testing is that they are all genetically identical, which means their responses to the drugs should be uniform rather than variable as seen in animals with different genetic make-ups.

After consulting with many independent scientists and experts in cloning, the U.S. Food and Drug Administration (FDA) decided in January 2008 that meat and milk from cloned animals, such as cattle, pigs and goats, are as safe as those from non-cloned animals. The FDA action means that researchers are now free to using cloning methods to make copies of animals with desirable agricultural traits, such as high milk production or lean meat. However, because cloning is still very expensive, it will likely take many years until food products from cloned animals actually appear in supermarkets.

Another application is to create clones to build populations of endangered, or possibly even extinct, species of animals. In 2001, researchers produced the first clone of an endangered species: a type of Asian ox known as a guar. Sadly, the baby guar, which had developed inside a surrogate cow mother, died just a few days after its birth. In 2003, another endangered type of ox, called the Banteg, was successfully cloned. Soon after, three African wildcats were cloned using frozen embryos as a source of DNA. Although some experts think cloning can save many species that would otherwise disappear, others argue that cloning produces a population of genetically identical individuals that lack the genetic variability necessary for species survival.

Some people also have expressed interest in having their deceased pets cloned in the hope of getting a similar animal to replace the dead one. But as shown by Cc the cloned cat, a clone may not turn out exactly like the original pet whose DNA was used to make the clone.

Here is the original post:

Cloning Fact Sheet - Genome.gov

Rick & Morty Theory: Space Beth Is Real Beth | Screen Rant – Screen Rant

Rick and Morty season 4's introduction of Space Beth raised the question of which Beth is a clone, and we think Space Beth is the real one.

Rick and Morty season 4brought the original Beth and clone Beth face to face, and even though no one in the show knows who is the real Beth, there is reason to believe "Space Beth" is the real one. The idea of cloning Beth came duringRick and Morty season 3. Beth was in the middle of a breakup with Jerry and sought adventure, but she put her future in Rick's hands.However, it wasn't until season 4 thatRick and Morty provided any exploration of what happened.

Two versions of Beth were featured inRick and Morty's season 4 finale, "Star Mort Rickturn of the Jerri." After a full season of Beth reunited with her family, Space Beth arrived as a cosmic warrior who spent her time battling the New Galactic Federation. Space Beth believed that she wasa clone after she discovered an implant in her neck,prompting her to return back to Earth to kill Rick. However, she learns that both Beths have such implants, adding to the confusion of who is real and who is a clone. Although both Beths were interested in learning who was real and who was the clone at first,Rick and Morty ended season 4with the entire family, except Rick, left in the dark. He begins toreveal his "Mind Blower" of the event (a recorded memory), which shows him cloning Beth, but then removing the labels from the cloning vats and rotate their placements repeatedly so he wouldn't know which Beth was real.

Related: Rick & Morty Theory: Beth Is Smarter Than Rick

SinceRick and Morty didn't provide any answers on which Beth is real and which is a clone,a fanbase built on wild theories has been left to create some more. The truth behind the two versions of Beth is one of the topics that has continued to be debated since season 4 ended, with cases to be made for either Beth being the clone. Since they were exactly the same at the end of the cloning process and Beth's uncertainty about what she wanted,the future for both Beths could just come down to where Rick put them.That said, one of them is definitively a clone, and even if Rick and Morty never answers the question,there's reason tobelieve that Space Beth is the real, or at least original Beth.

Space Beth's trajectory as a character falls in line with what Beth wanted for herself, based on her discussion about cloning with Rick. Sheexpressed a desireto go have more adventures after spending time in Froopyland with Rick and realizing that she's more like her father than she thought. Space Beth being the real Beth means she finally got the chance to break free of her mundane life and find happiness elsewhere. Although this would mean that the real Beth also abandoned her family, it was already fractured at this time. This arc gives Beth some agency in her story, instead of simply coming to a realization that she was happy all along and just didn't realize it. Plus, it's not like this would be the first time a Sanchez left their family behind to pursue their own interests, so this reveal would further illustrate how similar Beth and Rick are.

Read more from the original source:

Rick & Morty Theory: Space Beth Is Real Beth | Screen Rant - Screen Rant

Jurassic Park: Why Frog DNA Was Used to Create The Dinosaurs – Screen Rant

Jurassic Park's science uses frog DNA is a notable addition to the incomplete genome of a dinosaur, and it also gives them very special abilities.

The originalJurassic Parkfilmreveals that frog DNA was used to help create the dinosaurs, causing a problem with InGen's plan to limit breeding. Released in 1993, Steven Spielberg's classic not onlyboastedground-breaking advancements inCGI technology, but it also explored thescientific phenomena of cloning. While the logistics are not fully explained in the movie, they still provide a compellinglookinto the reemergence of dinosaurs.

When paleontologist Dr. Alan Grantand the team first arrive at the Jurassic Park Visitor Center, they are treated to a tour by John Hammond, founder of the park and of InGen, the company which makes dinosaur cloning possible. Their first stop includes a filmnarrated by Mr. DNA, the animated helix, who explains how the dinosaurs came to be. In simplified terms, scientists were able to extract dinosaur blood from prehistoric mosquitos preserved in amber. Because most of the samples' genomes were incomplete, geneticists needed something to, as Mr. DNA says, "fill in the holes and complete the code." This is where frog DNAcamein.

Related: Jurassic Park: All 6 Dinosaurs That Appear In The First Movie Explained

Frog DNA serves as both an easy, uncomplicated solution to the dinosaurs' genetic sequence and a plot device for later on in the film. It's that DNA solution that is responsible foreverydinosaur in the Jurassic Park series, like the T-Rex and Velociraptor before the later movies move into more overt genetic splicing. It'scombinedwith the dinosaurs' DNA sequence to make a finalized version for fertilization, filling in the gaps from degradation over the thousands of years since their extinction. In the film, it's only frog DNA that was used to serve the plot and explain how some dinosaurs have been able to change sex, while the original book uses a number of additional options. Fundamentally, it serves two other purposes too. Not only does it foreshadow the franchise's genetic tinkering and establishes that Dr Henry Wu's morals come second to his scientific drive,while adding an accessible means to explain how the amber extraction method can possibly lead to full sequence DNA cloning.

Michael Crichton's novel, on which the movie is based, provides a complex analysis of the differentchicken and amphibian genomes used in creating and boosting the growth of dinosaurs.Jurassic Park'sfilmmakers likely wanted to makethe process as simple as possible for audiences to understand, sofrog DNAbecame the sole additionalinsertion into the dinosaurs' biological makeup. Frog DNAis mentioned again in a later scene, when Dr. Grant, Lex, and Tim,discover freshly-hatched eggs outside of the lab. According to Dr. Wu, the head geneticist of the park's lab, all dinosaurs are programmed to be female, so breeding should be impossible. Upon finding the eggs, Dr. Grant remarks that some West African frogscan alter their sex in a single-sex space.Bymarrying a frogs genetic code with the dinosaurs', scientists gave dinosaursthe frogs ability to change sex and, therefore, mate. However, what type of frog DNA was actually used and whether the scientists knew about this trait from their research remains unclear.

Here is the original post:

Jurassic Park: Why Frog DNA Was Used to Create The Dinosaurs - Screen Rant

Critical steps outlined with property transfers and trust cloning | nestegg – nestegg.com.au

array(1) {[0]=>&object(stdClass)#5134 (52) {["id"]=>string(5) "15670"["title"]=>string(37) "Capitalising on the COVID-19 pandemic"["alias"]=>string(37) "capitalising-on-the-covid-19-pandemic"["introtext"]=>string(208) "

More time at home means many Australians now have the opportunity to re-assess their lifestyle and spending habits and set some serious saving goals. So how can you actually go about it?

In this episode of The nestegg Podcast, host Grace Ormsby is joined by Melbourne-based Reventons Billie Christofi to talk all things finance and the impact of isolation on our hip pockets.

In stage 4 lockdown, Billie shares the importance of going back to basics when it comes to budgeting, methods to re-assess spending habits, and some of the less conventional ways people can boost their wealth at this time.

Thanks Billie, for sharing your insights with the nestegg podcast team!

Have an investment story to share?Get in touch at[emailprotected]and you might get featured on an upcoming episode!

");googletag.cmd.push(function() { googletag.display('div-gpt-ad-1574384856617-0'); });}

See the original post:

Critical steps outlined with property transfers and trust cloning | nestegg - nestegg.com.au

Global Hard Drive Cloning Software Market Expected To Reach Highest CAGR By 2026: Acronis, Macrium Reflect, Todo Backup, DAEMON Tools, MiniTool etc. -…

Introduction: Global Hard Drive Cloning Software Market, 2020-26

A new versatile research report on Global Hard Drive Cloning Software market is aimed at promising a unique approach towards unravelling current and past market developments that collectively influence future growth predictions and market forecasts that allow market players in delivering growth specific business decisions.

The report serves as an ideal tool to instigate innovative market specific developments and subsequent growth projections. The study is a proposal and synopsis to orchestrate systematic data scavenging procedures amongst market participants.

Vendor Landscape

AcronisMacrium ReflectTodo BackupDAEMON ToolsMiniToolNovaBACKUPClonezillaAOMEI BackupperIperius BackupActive Disk ImageOandO DiskImageAOMEI Image Deploy

Available Sample Report in PDF Version along with Graphs and [emailprotected] https://www.orbisresearch.com/contacts/request-sample/4242204?utm_source=puja

The report also segregates various players into broad categories of novice aspirants and established market participants with elaborate success stories and investment discretion that fortify their footing amidst staggering competition and fast expanding competition isle.

Market Segments: Global Hard Drive Cloning Software MarketAimed at delivering market relevant information to initiate healthy growth prognosis amongst market participants. A detailed sectional representation on market segmentation has also been flagged in the report based on which global Hard Drive Cloning Software market identifies type, application and region as major segment types.

Segmentation by Type:

Cloud-basedWeb-based

Segmentation by Application:

Large EnterprisesSMEs

Report Offerings in a Gist: To identify correctly major underlying market forces that gradually underpin growth To comprehend future growth potential of the mentioned segments, inclusive of geographical outlook. A thorough evaluation of the entire competitive landscape gamut has been analyzed, isolating growth rendering strategies and industry forerunners To correctly isolate growth enablement determinants. The report lends clarity in understanding the commercial viability of the Hard Drive Cloning Software market ecosystem.

Read complete report along with TOC @ https://www.orbisresearch.com/reports/index/global-hard-drive-cloning-software-market-size-status-and-forecast-2020-2026?utm_source=puja

COVID-19 Impact AnalysisThis intensively researched report presentation has been prepared in real time parlance, rendering substantial attention towards COVID-19 outbreak that has lately wreaked unprecedented damage across industries, stagnating growth.

Based on extensive geographical scope and specific vendor activities across diverse regional pockets, global Hard Drive Cloning Software market is well segregated into specific nations such as Argentina and Brazil in South America. Additionally, other nations such as China, South Korea, Taiwan, Australia. Additional details on European growth hubs such as France, Italy, Germany, Netherlands have also been included in the report, followed by details on North America and MEA.

Competition EvaluationThe competitive landscape specific to global Hard Drive Cloning Software market further illustrates relevant growth favoring information pertaining to the vendor landscape with a specific focus on corporate growth strategies embraced by leading players, followed religiously by other relevant contributing players along with notable investors and stakeholders striving to etch lingering growth spurts despite high intensity competition and catastrophic developments.

In-depth research findings reflected in this report opine that despite the unprecedented outbreak and lingering implications of COVID-19 and its reformatory reforms reflected across industries, the immediate and future specific implications have been thoroughly classified and elaborated in the report to encourage unbiased market discretion.

Global Hard Drive Cloning Software market Key Report Highlights: This in-depth research documentation offers an illustrative overview of the entire market outlook with details on scope, executive summary and market segments The report also includes sections on competitive spectrum, highlighting major players, with detailed assessment of supply chain management, competition dynamics and growth objectives. Other crucial details on Porters Five Forces assessment, SWOT analysis and data triangulation methods have also been included in the report. Other relevant details on production patterns, growth rate, market share of each of the segments have also been pinned in the report. The report also houses crucial analytical details on revenue share and sales projections, besides volumetric estimations of each of the product segments have also been highlighted in the report to encourage unfaltering market decisions and sustainable revenue streams in global Hard Drive Cloning Software market.

A dedicated chapter on COVID-19 analysis has therefore been included in this versatile report to encourage future-ready business discretion aligning with post COVID-19 market environment.

Shoot your queries at:@ https://www.orbisresearch.com/contacts/enquiry-before-buying/4242204?utm_source=puja

These crucial market relevant information are estimated to trigger tremendous growth returns and sustain market stability through the forecast tenure.

About Us:Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155

Visit link:

Global Hard Drive Cloning Software Market Expected To Reach Highest CAGR By 2026: Acronis, Macrium Reflect, Todo Backup, DAEMON Tools, MiniTool etc. -...

There Many Different COVID-19 Tests Which One to Choose? – SciTechDaily

Various diagnostic techniques can be used for sensing the RNA of SARS-CoV-2. Credit: Saadet Alpdagtas and Elif Ilhan

Different diagnostic techniques are appropriate at different stages of coronavirus infection. Using the right one is crucial for rapid diagnosis to help end the pandemic.

Until a vaccine is available, curbing the coronavirus pandemic relies heavily on how quickly a potentially exposed individual can be tested and quarantined. However, the current diagnostic techniques vary in reliability and relevance, so an understanding of which test is most appropriate for a given circumstance is necessary to avoid false reports.

Researchers from Van Yuzuncu Yil University, Marmara University, Yildiz Technical University, and Istanbul Yeni Yuzyil University evaluated the available diagnostic techniques and determined key steps required for better testing moving forward. They present their findings in the journalAPL Bioengineering, from AIP Publishing.

Rapid diagnosis and rapid isolation are the key factors for prevention of the pandemic, said Oguzhan Gunduz, one of the authors.

Laboratory tests that target the viruss genes known as real-time reverse transcription-polymerase chain reaction assays are currently the gold standard for testing. But according to the Food and Drug Administration, these could give false negatives.

These tests depend on the presence of antibodies, which may not have yet been developed in the early stages of infection. Since different antibodies appear at different stages, diagnostic tests must be chosen to target the appropriate immune response based on when an individual is believed to have been infected.

There is not any available single test for the entire stage of the disease, Gunduz said. However, I think it may be possible to detect the attack at any stage of the disease with nano-based sensor technologies.

The group emphasizes point-of-care testing as an urgent objective. These types of tests would help detect the virus on site without the need for laboratory equipment or specialized personnel, eliminating or reducing the wait time between testing and obtaining results.

A quite sensitive test that can measure the existent tiny number of viral particles, or any parameter related to the particle weight, structure, charge, diameter can provide rapid and early diagnosis, said Gunduz.

When asked about the potential for a more comfortable testing method, he stressed that this depends on the sampling method and its sensitivity. A fingertip blood test or a saliva test could potentially be underway, though these have their own drawbacks.

There are such tests, but they come up with accuracy and specificity issues, Gunduz said.

Reference: Evaluation of current diagnostic methods for COVID-19 by Saadet Alpdagtas, Elif Ilhan, Ebru Uysal, Mustafa Sengor, Cem Blent stndag and Oguzhan Gunduz, 1 December 2020, AIP Bioengineering.DOI: 10.1063/5.0021554

More:
There Many Different COVID-19 Tests Which One to Choose? - SciTechDaily

Coated nanoparticles survive immune system and deliver drugs – ScienceBlog.com

The great thing about ionic liquids is that every small change you make to their chemistry results in a big change in their properties, said Christine Hamadani, a former graduate student at SEAS and first author of the paper. By changing one carbon bond, you can change whether or not it attracts or repels proteins.

Hamadani is currently a graduate student at Tanners lab at the University of Mississippi.

The researchers coated their nanoparticles with the ionic liquid choline hexenoate, which has an aversion to serum proteins. Once in the body, these ionic-liquid coated nanoparticles appeared to spontaneously attach to the surface of red-blood cells and circulate until they reached the dense capillary system of the lungs, where the particles sheared off into the lung tissue.

This hitchhiking phenomenon was a really unexpected discovery, said Mitragotri. Previous methods of hitchhiking required special treatment for the nanoparticles to attach to red blood cells and even then, they only stayed at a target location for about six hours. Here, we showed 50 percent of the injected dose still in the lungs after 24 hours.

The research team still needs to understand the exact mechanism that explains why these particles travel so well to lung tissue, but the research demonstrates just how precise the system can be.

This is such a modular technology, said Tanner, who plans to continue the research in her lab at University of Mississippi. Any nanoparticle with a surface change can be coated with ionic liquids and there are millions of ionic liquids that can be tuned to have different properties. You could tune the nanoparticle and the liquid to target specific locations in the body.

We as a field need as many tools as we can to fight the immune system and get drugs where they need to go, said Mitragotri. Ionic liquids are the latest tool on that front.

The research was co-authored by Morgan J. Goetz.

Visit link:
Coated nanoparticles survive immune system and deliver drugs - ScienceBlog.com

Global Avian Influenza Vaccines Market Qualitative And Quantitative Research Incorporating Impact Of Economic And Non-Economic Aspects By 2027||Harbin…

Avian influenza vaccines marketis expected to gain market growth at a potential rate of 16.34% in the forecast period of 2020 to 2027. Increasing awareness among the people regarding the availability as well as benefits of avian influenza vaccines which will help in boosting the growth of the market.

Download Free Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on thisIndustry@https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-avian-influenza-vaccines-market

The major players covered in the avian influenza vaccines market report are

Analysis based on

Avian influenza vaccines Market report Synopsis

Global Avian Influenza Vaccines Market Scope and Market Size

Avian influenza vaccines market is segmented on the basis of vaccine type, application, and strain. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT GET FREECOVID-19SAMPLE@https://www.databridgemarketresearch.com/covid-19-impact/global-avian-influenza-vaccines-market

Avian Influenza Vaccines Market Country Level Analysis

Avian influenza vaccines market is analysed and market size information is provided by country by vaccine type, application and strain as referenced above.

The countries covered in the avian influenza vaccines market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America dominates the avian influenza vaccines market due to rising awareness among the people along with growing number of research and development activities in the region while the Asia-Pacific region is expected to grow at the highest growth rate in the forecast period of 2020 to 2027 due to the rising occurrences ofinfectionalong with increasing dependence on poultry for protein.

Table of Contents:

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart) @https://www.databridgemarketresearch.com/toc/?dbmr=global-avian-influenza-vaccines-market

About Us:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. GetCustomizationandDiscounton Report by emailingsopan.gedam@databridgemarketresearch.com. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email:Corporatesales@databridgemarketresearch.com

Link:
Global Avian Influenza Vaccines Market Qualitative And Quantitative Research Incorporating Impact Of Economic And Non-Economic Aspects By 2027||Harbin...